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Abstract
Deep learning has been successfully applied to a variety of image classification
tasks. In the last few years, starting with the ground-breaking results of AlexNet
at the ImageNet Large Scale Visual Recognition Challenge (ILSVRC), there has
been tremendous and rapid growth in deep learning and its potential applications.
There has been keen interest to apply deep learning in the medical domain, par-
ticularly specialties that heavily utilize imaging, such as dermatology, pathology,
radiology, and ophthalmology.
One issue that may hinder application of deep learning to the medical domain
is the vast amount of data necessary to train deep neural networks (DNNs). Im-
ageNet comprises over 14 million labeled images, but because of regulatory and
privacy issues associated with medicine, and the generally proprietary nature of
data in medical domains, obtaining large datasets to train DNNs is a challenge,
particularly in the ophthalmology domain.
Transfer learning is a technique developed to address the issue of applying
DNNs for domains with limited data. Prior reports on transfer learning have ex-
amined custom networks to fully train or used a particular DNN for transfer learn-
ing. However, to the best of my knowledge, no work has systematically examined
a suite of DNNs for transfer learning for classification of diabetic retinopathy, di-
abetic macular edema, and two key features of age-related macular degneration.
This work attempts to investigate transfer learning for classification of these
ophthalmic conditions. Part I gives a condensed overview of neural networks and
the DNNs under evaluation. Part II gives the reader the necessary background
concerning diabetic retinopathy and prior work on classification using retinal fun-
dus photographs. The methodology and results of transfer learning for diabetic
v
retinopathy classification are presented, showing that transfer learning towards
this domain is feasible, with promising accuracy.
Part III gives an overview of diabetic macular edema, choroidal neovasculariza-
tion and drusen (features associated with age-related macular degeneration), and
presents results for transfer learning evaluation using optical coherence tomography
to classify these entities.
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Introduction
Recent advances in hardware, such as graphics processing units (GPUs), have
made possible practical application of deep learning. Since the breakthrough work
of AlexNet[6] at the ImageNet Large Scale Visual Recognition Challenge (ILSVRC)
in 2012, there has been rapid and tremendous growth in deep learning, and at-
tempts to apply it towards domains such as medical imaging. One practical issue
is obtaining the vast amounts of data necessary for training. Unlike the ImageNet
dataset, which numbers on order of tens of millions of images, there are limited
open access datasets in ophthalmology. At present time, the largest public domain
diabetic retinopathy photography dataset numbers on order of tens of thousands.
The issue of limited open access datasets likely will not improve because of strict
regulatory and privacy constraints placed on medical data.
Transfer learning is a technique developed to address the issue of applying deep
learning for domains with limited data[1]. The basic idea is to leverage the funda-
mental learning blocks built with a particular deep neural network (DNN), such
as ResNet, and to “re-train” the DNN for a particular domain of interest. Thus,
one can utilize the strong “fixed feature extractor” capabilities of a DNN built on
the millions of training examples from ImageNet to detect features common to all
domains, such as object edges, and then re-train just the “top layer” for classifi-
cation with the limited training data from a particular target domain.
In this paper, an overview of neural networks and the DNNs evaluated for
transfer learning is presented in part I. A condensed review is provided of the un-
derlying algorithm and mathematics involved with back-propagation and training
the neural network. In part II, the reader is provided with a background of diabetic
retinopathy: the prevalence numbers and magnitude of the projected numbers of
1
an increasing population of diabetic patients, and the limited supply of trained
ophthalmologists and other screening readers able to keep up with the rising de-
mand. An overview of diabetic retinopathy classification is provided as well as
the dataset used in this study (from the Kaggle Diabetic Retinopathy Detection
competition). Lastly, the methodology used to evaluate transfer learning with a
suite of DNNs towards diabetic retinopathy classification is presented. The results
indicate that certain modes of transfer learning yield higher classification perfor-
mance, and while all of the DNNs do well, certain DNNs may be better candidates
for utilization in automated screening of diabetic retinopathy with deep learning.
In part III, this report details the evaluation of transfer learning for classifica-
tion of diabetic macular edema, choroidal neovascularization, and drusen (features
associated with age-related macular degeneration) using a different imaging modal-
ity called optical coherence tomography (OCT). OCT has emerged as a pivotal
imaging modality in ophthalmology and critical for the diagnosis and managment
of many retinal diseases. Methodology similar to part II is used to evaluate transfer
learning for classification of these disease entities. The results concur with find-
ings in part II, supporting that deep learning has strong promise for accurately
classifying these eye conditions.
2
Part I
Deep Learning
3
Chapter 1
Background: Deep Learning
This chapter is a brief overview of deep learning concepts, adapted from a set
of course lecture notes[2]. For further details, the reader is refered to the online
reference by Goodfellow et al. [3].
1.1 Neural Networks
A neural network is composed of layers of artificial neurons, where each layer
computes some function of the layer beneath it (figure 1.1). The input is mapped
in a feed-forward fashion to the output. In this report, only feed-foward models
are considered (no cycles).
Neural networks have their origins in the 1940’s and 1950’s and in particular
the Perceptron which were single layer networks with a simple learning rule (see
[3], Introduction chapter). Practical ways to train these networks were developed
in the mid-1980’s with the back-propogation algorithm (see [3], chapter 6).
In the simpliest design, the input to a neural network, denoted by x, is a [nx1]
vector (figure 1.2). The parameters are the weights, denoted by w (also a [nx1]
4
Figure 1.1: Schematic representation of a feed-foward neural network model. Re-
produced from [2].
vector), and a bias scalar, denoted by b. An activation, denoted by a, is a scalar
defined by:
a =
n∑
i=1
xiwi + b (1.1)
A point-wise non-linear function, denoted by σ(·), is then applied to generate
the output, y = f(a) = σ(
∑n
i=1 xiwi + b).
The structure is modified slightly in the case of multiple outputs (figure 1.3).
The input remains x, a [nx1] vector. There are m neurons, and thus a [nxm]
weight matrix W and [mx1] bias vector b. The [mx1] output vector y is defined
by y = σ(Wx + b).
Some choices for the non-linearity function σ include: (1) the sigmoid function
σ(z) = 1
1+e−z ; (2) the Tanh function, σ(z) = tanh(z); (3) the Rectified Linear
(ReLU) function, σ(z) = max(z, 0); and (4) the Leaky ReLU (PReLU) σ(z) =
1[z > 0]max(0, z) + 1[z < 0]max(0, αz). The pros and cons of each function are
5
Figure 1.2: Schematic representation of a feed-foward neural network model with
parameters (weights and bias) and single output. Reproduced from [2].
discussed in [2] and [3].
A neural network is typically composed of multiple layers of neurons (figure
1.4). This is an acyclic structure with an assumption of full connections between
layers. The layer(s) between the input and output layers are called hidden. Other
terminology for this type of structure includes Artificial Neural Networks (ANN),
Multi-layer Perceptron (MLP), and a fully-connected network. By convention, the
number of layers is equal to the number of hidden layers plus the output layer
(i.e. , excludes the input layer). An sample schematic of a multi-layered network
is shown in figure 1.5.
The issue of architecture selection, specifically how to pick the number of layers
and units per layer, is difficult to determine. For fully connected models, it appears
6
Figure 1.3: Schematic representation of a feed-foward neural network model with
parameters (weights and bias) and multiple outputs. Reproduced from [2].
that 2-3 layers seems to be the most that can be effectively trained[2]. Moreover,
the number of parameters grow with the square of the number of units per layer and
with a large number of units per layer, overfitting may be an issue. Convolutional
Neural Networks (CNNs), discussed below, address this limit in fully connected
networks.
Once a model architecture has been selected, the next step is to train the model.
The details of the procedure are presented in [2] and [3]. Briefly, the steps include:
• Given the dataset of input x and output y, pick an appropriate cost function,
C.
• Forward pass the input examples throught the model to arrive at the predic-
tions.
• Calculate the error using the cost function C to compare the predictions.
7
Figure 1.4: Schematic representation of a feed-foward neural network model with
a hidden layer and multiple outputs. Reproduced from [2].
Figure 1.5: Schematic representation of a feed-foward neural network model with
multiple hidden layers and multiple outputs. Reproduced from [2].
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• Apply back-propogation to pass the error back through the model, adjusting
the parameters to minimize the energy E.
• Once the gradients are established, use Stochastic Gradient Descent (SGD)
to update the network weights.
In SGD, we start with some initial set of parameters, denoted by θ0, and the
updates are defined by θk+1 ← θk + η∆θ, where k is an iteration index, η is the
learning rate, and the gradients ∆θ = ∂E
∂θ
.
Figure 1.6 shows a schematic for computing gradients in a multi-stage archi-
tecture, where the model has N layers. Each layer, i, has a vector of weights
Wi. Forward propagation takes the input x and passes it through each layer Fi,
such that xi = Fi(xi−1,Wi). The prediction, xn, is the output of the top layer
and the cost function, C, compares xn to y. The overall energy, E, is defined by
E =
∑M
m=1C(x
m
n , y
m), where m is the number of inputs.
Back-propagation is performed via the chain-rule. In the most general case,
consider input vector x, a [nx1] column vector:
x =

x1
x2
...
xn

(1.2)
and consider a function y = F(x) such that y is a [mx1] vector, then the [mxn]
9
Jacobian matrix is given by:
∂y
∂x
=

∂y1
∂x1
∂y1
∂x2
. . . ∂y1
∂xn
...
...
...
...
∂ym
∂x1
∂ym
∂x2
. . . ∂ym
∂xn
 (1.3)
Recall the chain rule for matrices: consider function h(x) = fn(fn−1(. . . (f1(x)))).
Let u1 = f1(x), ui = fi(ui−1), z = un = fn(un−1). Then, the derivative is given by
a product of matrices:
dz
dx
∣∣∣∣
x=a
=
dz
dun−1
∣∣∣∣
un−1=fn−1(un−2)
· dun−1
dun−2
∣∣∣∣
un−2=fn−2(un−3)
· · · du2
du1
∣∣∣∣
u1=f1(a)
· du1
dx
∣∣∣∣
x=a
(1.4)
The energy, E, is computed as the sum of the costs associated to each training
example xm, ym:
E(θ) =
M∑
m=1
C(xmn , y
m; θ) (1.5)
and its gradient is:
∂E
∂θi
=
M∑
m=1
C(xmn , y
m; θ)
∂θi
(1.6)
Express the cost function as C(xn, y; θ) = C(Fn(xn−1, wn), y) with θ = [w1, w2, . . . , wn].
Then,
∂C
∂wn
=
∂C
∂xn
· ∂xn
∂wn
=
∂C
∂xn
· ∂Fn(xn−1, wn)
∂wn
(1.7)
There are various choices for the cost function C (see [3]). One common selection
is the Euclidean loss:
C(xn, y) =
1
2
‖xn − y‖2 (1.8)
and thus the gradient is ∂C
∂xn
= xn−y. Apply the chain rule to compute the gradient
10
with respect to wi:
∂C
∂wi
=
∂C
∂xn
· ∂xn
∂xn−1
· ∂xn−1
∂xn−2
· · · ∂xi+1
∂xi
· ∂xi
∂wi
(1.9)
Through back-propagation, if we have the value of ∂C
∂xi
we can compute the gradient
of the layer below as ∂C
∂xi−1
= ∂C
∂xi
· ∂xi
∂xi−1
. Thus, layer i has two inputs, xi−1 and ∂C∂xi .
At layer i, compute the derivatives ∂Fi(xi−1,wi)
∂xi−1
and ∂Fi(xi−1,wi)
∂wi
and obtain outputs
xi = Fi(xi−1, wi) and ∂C∂xi−1 =
∂C
∂xi
· ∂Fi(xi−1,wi)
∂xi−1
. Then, the weight update equations
are applied: ∂C
∂wi
= ∂C
∂xi
· ∂Fi(xi−1,wi)
∂wi
and wk+1i = w
k
i + ηt
∂E
∂wi
.
In summary, the backpropagation algorithm involves: (1) a forward pass where
for each training example we compute the output for all the layers, xi = Fi(xi−1, wi);
(2) a backwards pass where we compute cost derivatives iteratively from top to
bottom ∂C
∂xi−1
= ∂C
∂xi
· ∂Fi(xi−1,wi)
∂xi−1
; and (3) compute gradients and update the weights.
The softmax function takes an un-normalized vector and normalizes it into a
probability distribution, such that after the softmax operation each element xi is
in [0, 1] and
∑
i xi = 1[3]. This function is useful for neural networks, so that the
un-normalized output can be mapped to a probability distribution over predicted
output classes. One softmax function can be implemented by:
σ(z)j =
e−βzj∑K
k e
−βzk
(1.10)
for j = 1, . . . , K and β ∈ R. It is often combined with the cross-entropy cost
function, E = −∑Mc=1 yo,c log(po,c), where M is the number of classes, y is binary
indicator (0 or 1) if class label c is the correct classification for observation o, and
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Figure 1.6: Schematic of computing gradients in a multi-stage neural network.
Reproduced from [2].
p is the predicted probability observation o is of class c (e.g. from the softmax).
A constant learning rate η is typically not optimal. Techniques to optimize the
learning rate, such as annealing of learning rate, AdaGrad, RMSProp, and ADAM,
are discussed further in [2] and [3]. A momemtum term can be added to the weight
update to encourage updates to follow the previous direction. This usually helps
speed up convergence. The update then become θk+1 ← θk + α(∆θ)k−1 − η∆θ,
where α is typically around 0.9.
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1.2 Convolutional Neural Networks
A convolutional neural network (CNN), a form of supervised learning, is a neu-
ral network with a specialized connectivity structure where higher stages compute
global, more invariant features (figure 1.7)[2]-[4]. The CNN model is feed-forward,
where input images are fed to convolution layer(s), non-linearities, pooling layers,
and finally to feature maps. They have been shown to be very successfully applied
towards handwritting recognition[5] and other recognition tasks (see [2]). The
convolutional layers apply a convolution operation1 with a fixed sized filter, e.g.
3x3 or 5x5, across the image. The filter is learned during training, and options
such as the stride, padding, and dilation2 can be set. The pooling layer3 helps to
reduce the spatial size of the representation, thus reducing the number of param-
eters and computation, and to prevent overfitting.
ImageNet4 is a large scale image database with over 14 million labeled images
and over 20K classes. The ImageNet Large Scale Visual Recognition Challenge
(ILSVRC) is an annual competition, which in 2012 saw a major breakthrough via
the AlexNet CNN of Krizhevsky et al. [6], achieving a top-1 and top-5 error rates of
39.7% and 18.9% which was considerably better than the previous state-of-the-art
results.
This section of the overview of deep learning will briefly review 5 DNNs that
were evaluated in this report. These networks are AlexNet, ResNet, DenseNet,
Inception v3, and VGG. Their variants and error rates on ImageNet are listed in
1See https://towardsdatascience.com/intuitively-understanding-convolutions-f
or-deep-learning-1f6f42faee1 for an overview of the convolution operation.
2See the PyTorch documentation at https://pytorch.org/docs/stable/nn.html for an
example implementation, torch.nn.Conv2d, discussing these options.
3See http://cs231n.github.io/convolutional-networks/#pool
4http://www.image-net.org/
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Figure 1.7: Schematic of a CNN (LeNet-5), reproduced from [4].
table 1.1. The suseqeuent subsections briefly review each network.
Table 1.1: Networks that were evaluated in this paper. Listed are the Top-1 and
Top-5 ImageNet 1-crop error rates (224x224)
Network Top-1 error Top-5 error
AlexNet 43.45 20.91
VGG-11 30.98 11.37
VGG-13 30.07 10.75
VGG-16 28.41 9.62
VGG-19 27.62 9.12
VGG-11 with batch normalization 29.62 10.19
ResNet-18 30.24 10.92
ResNet-34 26.70 8.58
ResNet-50 23.85 7.13
ResNet-101 22.63 6.44
ResNet-152 21.69 5.94
Densenet-121 25.35 7.83
Densenet-169 24.00 7.00
Densenet-201 22.80 6.43
Densenet-161 22.35 6.20
Inception v3 22.55 6.44
1.2.1 AlexNet
The architecture of AlexNet is shown in figure 1.8[6]. This network has 60
million parameters and 500,000 neurons, consists of 5 convolutional layers, some of
which are followed by max-pooling layers, and two globally connected layers with
a final 1000-way softmax. To speed up training, they used a GPU implementa-
tion and reduced overfitting in the globally connected layers by employing a new
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regularization method.
Figure 1.8: Schematic of AlexNet, reproduced from [6].
1.2.2 ResNet
Deep Residual Networks (ResNets) were introduced with the observation that
deeper neural networks are more difficult to train[7]. The ResNet authors point
out that with increasing network depth, accuracy gets saturated and adding more
layers to a suitably deep model leads to higher training error (see their example in
figure 1.9).
Their solution to the degradation problem is to explicitly let the stacked layers
fit a residual mapping. They recast the original mapping into F(x)+x (figure 1.10),
with the hypothesis that it is easier to optimize the residual mapping compared
to the original, unreferenced mapping. They describe that their formulation of
F(x) + x can be realized by “shortcut connections,” which skip one or more layers
(in their case the shortcut connectios simply perform the identity mapping, and
their outputs are added to the outputs of the stacked layers).
The authors report that: 1) their extremely deep residual nets are easy to
optimize, but the counterpart “plain” nets (that simply stack layers) exhibit higher
training error when the depth increases (see figure 1.11); and 2) their deep residual
nets can easily enjoy accuracy gains from greatly increased depth, producing results
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substantially better than previous networks. The authors state that “this strong
evidence [of excellent generalization performance in image classification, detection
and localization tasks] shows that the residual learning principle is generic, and
we expect that it is applicable in other vision and non-vision problems.” This is
a motivating rationale to evaluate ResNet for transfer learning in parts II and III.
The architecture of a ResNet variant (ResNet-34) is shown in figure 1.12.
Figure 1.9: Increasing training and test error on CIFAR-10 with increasing network
layers, reproduced from [7].
1.2.3 DenseNet
Densely Connected Convolutional Networks (DenseNets)[8] were recently in-
troduced as a technique to address the “vanishing gradient” issue. Specifically,
the DenseNet authors point out that with increasingly deep CNNs as informa-
tion about the input or gradient passes through many layers, it can vanish and
“wash out” by the time it reaches the end (or beginning) of the network. Vari-
ous techniques, such as those introduced with ResNets, attempt to create short
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Figure 1.10: Redisual learning: a building block, reproduced from [7].
Figure 1.11: ResNet training on ImageNet, reproduced from [7].
paths from early layers to later layers to deal with this issue. The designers of
DenseNet created an architecture to ensure maximum information flow between
layers in the network, by connecting all layers (with matching feature-map sizes)
directly with each other. A schematic of their model is shown in figure 1.13. In
contrast to ResNet, DenseNet never combines features through summation before
they are passed into a layer, rather it combines features by concatenating them.
The “denseness” occurs because this network introduces L(L+1)
2
connections in an
L-layer network, instead of just L in traditional architectures.
The authors point out that a possibly counter-intuitive effect of this dense con-
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Figure 1.12: ResNet-34 and VGG-19 architecture, reproduced from [7].
nectivity pattern is that it requires fewer parameters than traditional convolutional
networks, as there is no need to relearn redundant feature-maps. Moreover, they
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argue that one big advantage of DenseNets is their improved flow of information
and gradients throughout the network, which makes them easy to train. Each
layer has direct access to the gradients from the loss function and the original
input signal, leading to an implicit deep supervision. This helps training of deeper
network architectures. Further, they observe that dense connections have a reg-
ularizing effect, which reduces overfitting on tasks with smaller training set sizes.
This potential advantage is an interesting area to investigate particularly for the
relatively small traning dataset used in part II of this report. In table 1.1, we
observe that the DenseNet variants performed comparable to the ResNet variants
on ImageNet.
Figure 1.13: Schematic of DenseNet, reproduced from [8].
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1.2.4 Inception
The motivation for the Inception network was to perform well even under strict
constraints on memory and computational budget[10]. Szegedy et al. stress that
although VGG has the compelling feature of architectural simplicity, this comes at
a high cost: evaluating the network requires a lot of computation. They describe
that the “main idea of the Inception architecture is based on finding out how an
optimal local sparse structure in a convolutional vision network can be approxi-
mated and covered by readily available dense components.”
One particular Inception implementation, GoogLeNet, devised a module called
inception module that approximates a sparse CNN with a normal dense construc-
tion (figure 1.14). The rationale for this being that the most of the activations
in a deep network are either unnecessary or redundant because of correlations be-
tween them. The Inception network keeps the width/number of the convolutional
filters of a particular kernel size small, and it uses convolutions of different sizes
to capture details at varied scales.
Figure 1.14: Schematic of an Inception module, reproduced from [10].
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1.2.5 VGG
Simonyan and Zisserman from the Visual Geometry Group (VGG), Department
of Engineering Science, University of Oxford, published the results of their CNN
in 2015[9]. They investigated the effect of the convolutional network depth on its
accuracy in the large-scale image recognition setting. They noted that their “main
contribution is a thorough evaluation of networks of increasing depth using an
architecture with very small (3x3) convolution filters, which shows that a significant
improvement on the prior-art configurations can be achieved by pushing the depth
to 1619 weight layers.” Their team secured the first and the second places in the
localization and classification tracks respectively [ImageNet Challenge 2014]. The
authors also note that their representations generalize well to other datasets, where
they achieve state-of-the-art results, thus the consideration of VGG for transfer
learning in this report. The architecture of the VGG-19 variant is shown in figure
1.12.
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Part II
Transfer Learning for
Classification of Diabetic
Retinopathy by Digital Fundus
Photography
22
Chapter 2
Background: Diabetic
Retinopathy
2.1 Diabetic Retinopathy
2.1.1 Prevalence
An estimated 25.6 million Americans aged 20 years or older have either been
diagnosed or remain undiagnosed with diabetes mellitus (11% of people in this age
group) [12], and about one-third are not aware that they have the disease [13].1
According to estimates based from the United States Census Bureau data, approx-
imately one-third of Americans are at risk of developing diabetes mellitus during
their lifetime [14].
Diabetic retinopathy (DR) is a leading cause of new cases of legal blindness
among working-age Americans and represents a leading cause of blindness in this
1Portions of this section courtesy of Diabetic Retinopathy Preferred Practice Pattern
(2017)[11].
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age group worldwide[15]. The prevalence rate for retinopathy for all adults with di-
abetes aged 40 and older in the United States is 28.5% (4.2 million people); world-
wide, the prevalence rate has been estimated at 34.6% (93 million people). An
estimate of the prevalence rate for vision-threatening DR (VTDR) in the United
States is 4.4% (0.7 million people). Worldwide, this prevalence rate has been
estimated at 10.2% (28 million people)[16]-[17]. Assuming a similar prevalence
of diabetes mellitus, the projected prevalence of individuals with any DR in the
United States by the year 2020 is 6 million persons, and 1.34 million persons will
have VTDR.
2.1.2 Stages
DR progresses in an orderly fashion from mild to severe stages when there is
not appropriate intervention. It is important to recognize the stages when referal
for treatment may be most beneficial. DR is classified into two catagories: non-
proliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy
(PDR).
The nonproliferative stages of DR are characterized by retinal vascular related
abnormalities, such as microaneurysms, intraretinal hemorrhages, venous dilation,
and cotton-wool spots. NPDR is further divided into mild, moderate, and severe
stages based on progressively worsening clinical features (see figure 2.1). Manag-
ment of NPDR involves close monitoring by an ophthalmologist or optometrist
and optimization of the patient’s glycemic control by an internist.
The proliferative stages of DR are characterized by abnormal pre-retinal neo-
vascular proliferation, such as on the optic nerve or elsewhere on the retina, which
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may ultimately lead to vitreous hemorrhage, tractional retinal detachment and irre-
versible vision loss. Treatment at the proliferative stages involves laser photocoag-
ulation, intravitreal injections of anti-vascular endothelial growth factor (VEGF)
agents, or surgery to repair a retinal detachment. Examples of PDR, with and
without laser treatment, are shown in figure 2.1.
2.1.3 Prior work on screening
Screening for DR is based upon a dilated retinal examination by a trained
ophthalmologist or optometrist, or by review of digital retinal images, which may
enable early detection of DR along with an appropriate referral [18]-[26].
A systematic review and meta-analysis of diagnostic accuracy for detection of
any level of DR using digital retinal imaging reviewed by certified readers (one field
with non-mydriatic imaging) showed 79% (C.I.2 74-83%) sensitivity and 96% (C.I.
95-98%) specificity.3 The authors conclude that screening generates a satisfactory
level of sensitivity and specificity, indicating the feasibility of manual DR screening
with digital imaging.
However, given the increasing prevalence of DR coupled with the fixed number
of trained eye care professionals or certified readers, current DR screening programs
that rely on expensive labor-intensive manual assessment may fail to address the
rising demand for screening, especially in rural or non-developed nations lacking
access to qualified screeners. To address this issue, screening with two alternate
modalities, crowdsourcing and automated retinal image analysis (ARIA) have been
2Confidence Interval (C.I.)
3See appendix B for an overview of sensitivity and specificity.
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explored.
2.1.3.1 Crowdsourcing
One study investigating crowdsourcing with Amazon Mechanical Turk (AMT)
found accuracy of 81.3% for distinguishing between normal and abnormal images
[27], while another study investigating AMT found accuracy ≥ 90% for distin-
guishing between normal vs. severely abnormal images[28]. Both studies reported
> 93% sensitivity, indicating that this screening modality has good potential to
address the increasing volume of images that will need to be screened with increas-
ing diabetes prevelance rates. However, as one of the study authors points out,
“crowdsourcing retinal image analysis does have inherent limitations. Almost by
definition, control over who is performing the image analysis has been ceded to
the abstract entity of ’the crowd,’ and efforts to exert choose or credential users
of an image grading platform run counter to the spirit of crowdsourcing. Oper-
ationally, this means that any crowdsourcing implementation requires meticulous
quality control to ensure the results seen in pilot-testing are maintained”[29].
2.1.3.2 Automated retinal image analysis (ARIA)
ARIA can be sub-classified based on techniques that rely on traditional com-
puter vision techniques and current state of the art deep learning techniques. A
review by Trucco et al. [30] found that 23 studies of various traditional ARIA
techniques achieved sensitivity ranging from 45-100% and specificity ranging from
67.4-99.31%. These systems were limited by relatively small datasets of images
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(range 6 to 16,670 images) that were mostly non-public. Moreover, the propri-
etary nature of these systems makes their general application to other datasets
challenging.
2.1.3.3 Deep Learning efforts
Gulshan et al. [36] published a landmark study that used the Inception-v3 neu-
ral network trained on 128,175 retinal images and validated on two independent
datasets consisting of 9,963 images (EyePACS-1) and 1,748 images (Messidor-2).
They found that using the first operating cut point with high specificity, approxi-
mating the specificity of ophthalmologists in the development set, on EyePACS-1,
the algorithms sensitivity was 90.3% and specificity was 98.1%. In Messidor-2,
the sensitivity was 87.0% and specificity was 98.5%. A second operating point
for the algorithm was evaluated, which had a high sensitivity on the development
set, reflecting an output that would be used for a screening tool. Using this op-
erating point, on EyePACS-1, the algorithm had a sensitivity of 97.5% (95% CI,
95.8%-98.7%) and a specificity of 93.4% (95% CI, 92.8%-94.0%). In Messidor-2,
the sensitivity was 96.1% (95% CI, 92.4%-98.3%) and the specificity was 93.9%
(95% CI, 92.4%-95.3%). The authors conclude that their evaluation of retinal
fundus photographs from adults with diabetes, an algorithm based on deep ma-
chine learning had high sensitivity and specificity for detecting referable diabetic
retinopathy.
Gulshan et al. applied transfer learning using the Inception-v3 network, and
described their methodology as “preinitialization using weights from the same net-
work trained to classify objects in the ImageNet data set were used.” However, it
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is unclear whether they used the Inception-v3 network as a fixed feature extractor
(i.e. “trained the top-layer”) or fine-tuned the network with their training dataset.
Moreover, it should be noted that they used a large number (54) of US-licensed
ophthalmologists or ophthalmology trainees in their last year of residency, all paid
for their work, to grade the training set. Further, US board-certified ophthalmol-
ogists with the highest rate of self-consistency were invited to grade the clinical
validation sets. Taken together, this methodology for grading the training and val-
idation sets likely provided a highly accurate set of labels, but may not reflect real-
world screening conditions where images may be graded by non-ophthalmologists.
Pratt et al. [37] applied a custom convolutional neural network (CNN) to clas-
sify stages of diabetic retinopathy from the Kaggle Diabetic Retinopathy Detection
competition.4 Their CNN architure is reproduced in figure 2.2. They defined speci-
ficity as the number of patients correctly identified as not having DR out of the true
total amount not having DR and sensitivity as the number of patients correctly
identified as having DR out of the true total amount with DR. Their definition of
accuracy was the amount of patients with a correct classification. They reported
that their final trained network achieved 95% specificity, 75% accuracy and 30%
sensitivity.
The high specificity reported in their study indicates that their CNN was able
to accurately detect normal healthy eyes. The authors point out (and as indicated
in section 3) that the majority of images from this Kaggle dataset was made up of
normal cases, and thus the CNN may suffer from over-fitting. The authors took
steps to address this issue by implementing real-time class weights into their CNN.
However, their low sensitivity result indicates issues in detecting truely diseased
4see section 3 for details of the Kaggle Diabetic Retinopathy Detection competition dataset.
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cases from normals (i.e. high false negatives).
The authors point out that “the low sensitivity, mainly from the mild and
moderate classes suggests the network struggled to learn deep enough features to
detect some of the more intricate aspects of DR. An associated issue identified,
which was certified by a clinician, was that by national UK standards around over
10% of the images in our dataset are deemed ungradable. These images were de-
fined a class on the basis of having at least a certain level of DR. This could have
severely hindered our results as the images are misclassified for both training and
validation.”
While the results from Gulshan et al. indicate excellent performance of the
Inception-v3 network for classification of diabetic retinopathy, their high sensitiv-
ity and specificity results may not reflect real-world performance since their mainly
properietary datasets (and public Messidor-2 dataset) were highly validated. Se-
lecting the optimal balance of sensitivity and specificity depends on the purpose
for which the test is used. Generally, a screening test should be highly sensitive,
whereas a follow-up confirmatory test should be highly specific[38]. The results of
Pratt et al. suggest that the applicability of deep learning as a screening method-
ology for real-world images may need further validation.
To my knowlege, no prior work has analyzed transfer learning applied to the
Kaggle Diabetic Retinopathy Detection competition dataset, which based on the
work of Pratt et al. may represent more real-world screening conditions where
images are misclassified. Furthermore, it is unclear if transfer learning via the
approach of using a pretrained model (e.g. one of the ResNet variants) as a fea-
ture extractor (“training the top layer”) vs. fine-tuning the DNN yields higher
accuracy. This paper presents the methodology and results of applying transfer
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learning using several standard DNNs trained on the ImageNet dataset with the
Kaggle Diabetic Retinopathy Detection competition dataset, and exploring the
accuracy of using these networks as feature extractors vs. fine-tuning them.
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(a) Normal fundus, no DR.
(b) Mild non-proliferative DR.
Shown are exudates and mi-
croaneurysm.
(c) Moderate non-proliferative
DR.
(d) Severe non-proliferative DR.
Shown are intra-retinal hemor-
rhages in 4 quadrants and exu-
dates.
(e) Proliferative DR. Shown are
neovascularization of the optic
nerve and pre-retinal hemor-
rhage.
(f) Proliferative DR treated
with laser. Pigmented laser
scars are seen.
Figure 2.1: Example images showing normal (2.1a) and worsening stages of DR
(2.1b-2.1f).
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Figure 2.2: CNN architecture of Pratt et al. . [37].
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Chapter 3
Methods
3.1 Diabetic Retinopathy Fundus Photographs
The dataset from the Kaggle Diabetic Retinopathy Detection competition [31]
was used for evlauation of transfer learning for classification of diabetic retinopa-
thy based on digital fundus photography. The task designated by this competition
was to create an automated analysis system capable of assigning a score based on
a diabetic retinopathy scale (elaborated below).
This dataset comprises a large set of high-resolution retina images taken under
a variety of imaging conditions. Retinal images for the competition were provided
by EyePACS 1 (http://www.eyepacs.com), a free platform for retinopathy screen-
ing. Briefly, EyePACS allows patients with diabetes to receive retinal evaluations
with a digital retinal camera during primary care visits or other eye screening set-
tings. The camera can be operated by a nurse or by other individuals who have
been technically trained and certified. The digital images are uploaded to the Eye-
1Eye Picture Archive Communication System
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PACS web site where they are interpreted online by trained and certified readers.
Recommendations for follow-up and treatment are then made by credentialed doc-
tors, and sent electronically to the patients electronic medical record or directly to
their primary care physician.
This dataset has a total of 88,702 JPEG2 images. The competition sponsor
pre-allocated 31,615 (35.6%) of these images for training, 3,511 (4.0%) for valida-
tion, and 53,576 (60.4%) for testing. Class labels were provided by the competition
for the training, validation, and test images. All images were rated by a certified
reader according to a standard diabetic retinopathy grading scale:
• Class 0 - No Diabetic Retinopathy present.
• Class 1 - Mild Non-proliferative Diabetic Retinopathy present.
• Class 2 - Moderate Non-proliferative Diabetic Retinopathy present.
• Class 3 - Severe Non-proliferative Diabetic Retinopathy present.
• Class 4 - Proliferative Diabetic Retinopathy present.
Examples of images from each class are show in figure 3.1. The distribution
of labels for the training, validation, and test datasets is listed in table 3.1. Note
that the relative distribution across classes for the training, validation, and test
datasets were kept nearly identical.
Rather than accuracy, the quadratic weighted kappa statistic3 was used as the
benchmark for evaluation of submissions for the Kaggle Diabetic Retinopathy De-
tection competition. Briefly, the quadratic weighted kappa is a chance-adjusted
2Joint Photographic Experts Group, see https://jpeg.org/
3See appendix B for an overview of quadratic weighted kappa.
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index of agreement. In machine learning it can be used to quantify the amount
of agreement between an algorithm’s predictions and some trusted labels of the
same objects. A generally agreed upon scale is: <0.20(Poor), 0.21-0.40(Fair), 0.41-
0.60(Moderate), 0.61-0.80(Good), and 0.81-1.00(Very good).
The top two submissions achieved quadratic weighted kappa scores of 0.84957
and 0.84478, respectively. The system employed by the top score used a pre-
processing step to compensate for different lighting conditions, the SparseCon-
vNet4, and Python/Scikit-Learn to train a random forest to combine predictions
from the two eyes into a single prediction, and output the final submission[32]. The
system that scored second place used a custom CNN described in their report[33].
They utilized a resampling strategy to compensate for the class imbalance of the
dataset and a “blending” algorithm for both patient eyes to increase performance.
Table 3.1: Distribution of labels across training, validation, and test sets for the
diabetic retinopathy dataset.
Class 0 Class 1 Class 2 Class 3 Class 4 Total
Training 23,229(73.5%) 2,199(7.0%) 4,763(15.0%) 786(2.5%) 638(2.0%) 31,615
Validation 2,581(73.5%) 244(7.0%) 529(15.0%) 87(2.5%) 70(2.0%) 3,511
Test 39,533(73.8%) 3,762(7.0%) 7,861(14.7%) 1,214(2.3%) 1206(2.3%) 53,576
3.2 Model selection and runtime configuration
Development and runtime were done on the High Performance Computing
(HPC) environment at New York University, specifically the HPC Prince Clus-
ter.5 All coding was done with Python 3.6.6. and PyTorch 0.4.1. on a Linux
4https://github.com/btgraham/SparseConvNet
5See https://wikis.nyu.edu/display/NYUHPC/Clusters+-+Prince for details about this
system.
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environment.
The networks listed in table 1.1 were evaluated. This set of 16 networks con-
sists of AlexNet, the 4 variants of VGG, one of the VGG networks with batch
normalization, the 5 variants of ResNet, the 4 variants of DenseNet, and the In-
ception network. A PyTorch transfer learning template6 was modified to run these
pre-built networks.
As a “baseline” evaluation, each of these 16 networks was evaluated as not
pretrained (i.e. the pretrained argument at model creation was set to False). The
process was then repeated with pretrained networks, i.e. the networks were loaded
with the weights from their repective training on the ImageNet dataset.
Within the pretrained/not pre-trained modes, each network was evaluated
twice: once in a configuration “fine tuning the convnet” and once as “fixed fea-
ture extractor.” As described in the PyTorch transfer learning tutorial[34], these
configurations are:
• Finetuning the convnet: Instead of random initializaion, we initialize the
network with a pretrained network, like the one that is trained on imagenet
1000 dataset. Rest of the training looks as usual.
• Fixed feature extractor: Here, we will freeze the weights for all of the network
except that of the final fully connected layer. This last fully connected layer
is replaced with a new one with random weights and only this layer is trained.
Rough guidelines for what type of transfer learning to use are discussed in [1].
The two main factors are the size of the new dataset (small or big), and its simi-
larity to the original dataset (e.g. ImageNet-like in terms of the content of images
6See https://pytorch.org/tutorials/beginner/transfer_learning_tutorial.html
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and the classes, or very different, such as microscope images). Clearly, the reti-
nal images are not similar to the ImageNet dataset, but what value is considered
“big” or “small,” though, is unclear. Hence, the rationale to experiment with both
training modes.
For the purpose of establishing a “not pre-trained” baseline analysis in this re-
port, the finetuning and fixed feature extractor modes were run with not pretrained
and pre-trained models, i.e. 4 possible combinations:
1. Not-pretrained network, fine-tuning.
2. Not-pretrained network, fixed feature extractor.
3. Pretrained network, fine-tuning.
4. Pretrained network, fixed feature extractor.
Data augmentation was done using torchvision.transforms, specifically with
transforms.RandomResizedCrop(224) and transforms.RandomHorizontalFlip()
for the training set, and transforms.Resize(256) and transforms.CenterCrop(224)
for the validation set. Training, validation, and test images were normalized using
transforms.Normalize([0.485, 0.456, 0.406], [0.229, 0.224, 0.225]), where
the first list specifies the mean and the second list specifies the standard deviation
of the 3 respective color channels. These values were as recommended[34] from the
ImageNet dataset. Unless otherwise noted in chapter 4,
• The networks were trained and validated over 10 epochs.
• Stochastic Gradient Descent (SGD) was used as the optimizer, with initial
learning rate of 0.001 and momentum of 0.9.
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• The StepLR learning rate scheduler was used, such that the learning rate
decayed by a factor γ = 0.1 every 7 epochs.
• Cross Entropy Loss was used to train the models with equal weighting across
the classes, unless noted otherwise in chapter 4.
The PyTorch code was cuda enabled and was submitted via the slurm workload
manager7 with one GPU. All statistical analysis was done with Python. Specifi-
cally, the scipy package was used to compute mean, median, standard deviation,
and the Wilcoxon signed-rank or Mann-Whitney U test (see appendix B). Accu-
racy, sensitivity, specifcity, and quadratic weighted kappa (see appendix B) were
calculated for a selected subset of networks.8
To assess if performance could be further improved, 3 modifications were eval-
uated for selected subsets of the networks: (1) increase the number of epochs to
50; (2) use an image pre-processing step; and (3) use class-adjusted weightings.
A selected subset of networks were run for 50 epochs to assess if the training or
validation loss and accuracy values significantly change after 10 epochs. In addi-
tion, a selected subset of networks were re-evaluated with an image pre-processing
step described by Graham[32]. This pre-procssing involved: (1) rescale the images
to have the same radius (500 pixels was chosen); (2) subtract the local average
color; the local average gets mapped to 50% gray; and (3) clip the images to 90%
size to remove the boundary effects. Two examples of the image pre-processing
are shown in figure 3.2.
To assess for underfitting or overfitting of the networks, the training to valida-
tion loss ratios were computed for each run and were plotted for comparisons. If the
7See https://slurm.schedmd.com/
8Quadratic weighted kappa was calculated using the routine available at https://github.c
om/benhamner/Metrics/blob/master/Python/ml_metrics/quadratic_weighted_kappa.py.
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training loss is much lower than validation loss (ratio <1) then this may indicate
that the network might be overfitting. If, on the other hand, roughly training loss
equals validation loss, the network may be underfitting[35]. Lastly, because of the
class imbalance where the majority (about 73%) of training, validation, and test
images are from Class 0 cases, class-adjusted weighting were evaluated (specific
weights passed to the Cross Entropy Loss function).
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(a) Class 0: no diabetic
retinopathy. (b) Class 1: mild non-
proliferative diabetic retinopa-
thy.
(c) Class 2: moderate non-
proliferative diabetic retinopa-
thy.
(d) Class 3: severe non-
proliferative diabetic retinopa-
thy.
(e) Class 4: proliferative dia-
betic retinopathy.
(f) Class 4: proliferative dia-
betic retinopathy treated with
laser.
Figure 3.1: Sample images from Kaggle Diabetic Retinopathy Detection competi-
tion.
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Figure 3.2: Diabetic retinopathy: example pre-processed images. Two images from
the training set. Original images on the left and preprocessed images on the right.
Reproduced from Graham[32].
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Chapter 4
Results
There was a total of 64 runs (16 networks x [pre-trained vs. not pre-trained]
x [fine-tuning vs. fixed feature extractor]). Table 4.1 shows the loss results for
the 16 networks that were evaluated. The results are grouped by not-pretrained
and pre-trained catagories, then by training or validation phases, and lastly by the
type of implementation (fine-tuning the network or using it as feature extractor).
The results of this table are summarized in the series of boxplots in appendix C,
figure C.1.
Similarly, table 4.2 shows the accuracy results for the networks that were evalu-
ated. The results in that table are also grouped by not-pretrained and pre-trained
catagories, then by training or validation phases, and lastly by the type of imple-
mentation (fine-tuning the network or using it as feature extractor). The results
of this table are summarized in the series of boxplots in appendix C, figure C.2.
Detailed loss and accuracy plots for each run are plotted in appendix C, specif-
ically figures C.3-C.18. The plots show loss or accuracy data over 10 epochs,
for training and validation. Each plot corresponds to one of the 64 network/pre-
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Table 4.1: Diabetic retinopathy: Network loss results. Shown are the loss
values for each network at the last epoch. Values are grouped by whether the
newtork was pre-trained or not pre-trained, the phase (training or validation), and
whether the network was used in fine-tuning or fixed feature extractor mode. All
networks were trained for 10 epochs.
Not-Pretrained Pre-Trained
Training Loss Validation Loss Training Loss Validation Loss
Fine Feature Fine Feature Fine Feature Fine Feature
Network Tuning Extractor Tuning Extractor Tuning Extractor Tuning Extractor
AlexNet 0.8548 0.8676 0.8538 0.8662 0.7475 1.1955 0.7431 0.9628
DenseNet-121 0.8597 0.8630 1.1321 0.8885 0.6261 0.8122 0.6333 0.7697
DenseNet-161 0.8607 0.8632 1.2018 0.9268 0.6067 0.7917 0.6162 0.7861
DenseNet-169 0.8607 0.8632 1.2018 0.9268 0.6217 0.8011 0.6461 0.7615
DenseNet-201 0.8616 0.8649 1.0251 0.9524 0.6177 0.8037 0.6839 0.7838
Inception-v3 0.8724 0.9367 0.8940 0.9249 0.6368 0.8719 0.6923 0.8061
ResNet-18 0.8602 0.8700 0.8644 0.8695 0.6467 0.8267 0.6616 0.8120
ResNet-34 0.8645 0.8792 0.8673 0.8705 0.6262 0.8172 0.6422 0.8312
ResNet-50 0.8631 0.9259 0.8934 0.8958 0.6361 0.7999 0.6277 0.7966
ResNet-101 0.8636 0.9273 1.1319 0.8891 0.6818 0.8055 0.6691 2.1481
ResNet-152 0.8675 0.9289 1.4395 0.9680 0.6493 0.7971 1.6231 0.8171
VGG-11 0.6198 0.9812 0.6193 0.8189 0.8540 0.8709 0.8510 0.8644
VGG-11-BN 0.8649 2.2726 0.8635 1.0197 0.6185 0.9871 0.6200 0.7945
VGG-13 0.8542 0.8781 0.8529 0.8654 0.6119 1.0039 0.5899 0.8230
VGG-16 0.8530 0.8714 0.8491 0.8639 0.6045 1.0107 0.5943 0.8451
VGG-16 0.8530 0.8714 0.8491 0.8639 0.6045 1.0107 0.5943 0.8451
VGG-19 0.8546 0.8746 0.8542 0.8651 0.6055 0.9577 0.5985 0.8153
trained or not pre-trained/fine-tuning or fixed feature extractor combinations.
Table 4.3 summarizes the mean, standard deviation, and median values for
loss across the models for the various combinations pre-trained vs. not pretrained,
training vs. validation phases, and fine-tuning vs. feature-extractor. Table 4.4
provides these statistics for the accuracy.
From tables 4.1-4.4 and the boxplots C.1 and C.2 in appendix C, several ob-
servations are made:
(1) The loss was generally lower in the pre-trained models compared to the not
pre-trained models when comparing fixed pairs of fine-tuning or feature extrac-
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Table 4.2: Diabetic retinopathy: Network accuracy results. Shown are the
accuracy values for each network at the last epoch for training phase and the best
accuracy for validation phase. Values are grouped by whether the newtork was
pre-trained or not pre-trained, the phase (training or validation), and whether the
network was used in fine-tuning or fixed feature extractor mode. All networks were
trained for 10 epochs.
Not-Pretrained Pre-Trained
Training Accuracy Validation Accuracy Training Accuracy Validation Accuracy
Fine Feature Fine Feature Fine Feature Fine Feature
Network Tuning Extractor Tuning Extractor Tuning Extractor Tuning Extractor
AlexNet 0.7347 0.7347 0.7351 0.7351 0.7520 0.6558 0.7579 0.7285
DenseNet-121 0.7347 0.7347 0.7345 0.7351 0.7921 0.7342 0.7960 0.7414
DenseNet-161 0.7347 0.7346 0.7345 0.7340 0.8003 0.7396 0.8038 0.7422
DenseNet-169 0.7347 0.7346 0.7345 0.7340 0.7952 0.7378 0.7921 0.7428
DenseNet-201 0.7347 0.7347 0.7351 0.7323 0.7957 0.7365 0.7938 0.7411
Inception-v3 0.7347 0.7241 0.7351 0.7354 0.7896 0.7299 0.7884 0.7368
ResNet-18 0.7347 0.7347 0.7351 0.7351 0.7847 0.7337 0.7952 0.7382
ResNet-34 0.7347 0.7346 0.7351 0.7351 0.7929 0.7339 0.7983 0.7410
ResNet-50 0.7347 0.7266 0.7351 0.7351 0.7894 0.7390 0.7975 0.7462
ResNet-101 0.7347 0.7265 0.7351 0.7351 0.7743 0.7359 0.7841 0.7448
ResNet-152 0.7347 0.7247 0.7351 0.7351 0.7851 0.7379 0.7739 0.7479
VGG-11 0.7961 0.6937 0.7986 0.7391 0.7347 0.7347 0.7351 0.7351
VGG-11-BN 0.7347 0.5982 0.7351 0.7351 0.7930 0.6912 0.8003 0.7380
VGG-13 0.7347 0.7345 0.7351 0.7351 0.7991 0.6877 0.8083 0.7417
VGG-16 0.7347 0.7347 0.7351 0.7351 0.7997 0.6865 0.8112 0.7365
VGG-19 0.7347 0.7347 0.7351 0.7351 0.7990 0.6979 0.8106 0.7383
Table 4.3: Diabetic retinopathy: Network loss statistics. Shown are the
mean, standard deviation, and median values for the loss data at the last epoch.
Results are across the 16 networks evaluated and are grouped by pre-trained vs.
not pre-trained networks, training or validation phase, and whether the networks
were used as fine-tuning or as fixed feature extractors.
Not-Pretrained Pre-Trained
Training Validation Training Validation
Fine Feature Fine Feature Fine Feature Fine Feature
Tuning Extractor Tuning Extractor Tuning Extractor Tuning Extractor
Mean 0.846 0.979 0.972 0.901 0.649 0.885 0.718 0.901
Stdv 0.059 0.336 0.195 0.048 0.063 0.112 0.242 0.325
Median 0.861 0.876 0.880 0.889 0.626 0.822 0.644 0.814
tor and training or validation phases. For instance, the losses in the pre-trained
validation phase for fine-tuning were lower than that of not pre-trained validation
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Table 4.4: Diabetic retinopathy: Network accuracy stastistics. Shown
are the mean, standard deviation, and median values for the accuracy data (best
accuracy over the epochs). Results are across the 16 networks evaluated and are
grouped by pre-trained vs. not pre-trained networks, training or validation phase,
and whether the networks were used as fine-tuning or as fixed feature extractors.
Not-Pretrained Pre-Trained
Training Validation Training Validation
Fine Feature Fine Feature Fine Feature Fine Feature
Tuning Extractor Tuning Extractor Tuning Extractor Tuning Extractor
Mean 0.739 0.721 0.739 0.735 0.786 0.720 0.790 0.740
Stdv 0.015 0.033 0.015 0.001 0.018 0.026 0.019 0.005
Median 0.735 0.735 0.735 0.735 0.792 0.734 0.796 0.741
phase for fine-tuning. These trends were graphically observed in the boxplots in
appendix C, in particular figure C.19a-C.19d shows that the pre-trained group
has lower loss than the not pre-trained group. This was confirmed in table 4.5,
which showed that there were statistically significant differences for each of the
pairwise pre-trained vs. not pre-trained comparisons, except for the pretrained vs.
not-pretrained training phase feature-extractor comparison (corresponds to figure
C.19b [see table 4.5 test no. 2]). The accuracy results showed the inverse pattern
as the loss results, where the accuracy was higher in 3 of 4 cases for pre-trained
networks (see table 4.2, table 4.4, table 4.5 [test no. 1-4], and the boxplots in figure
C.20a-C.20d).
(2) Holding the pre-trained or not pre-trained variable fixed, the loss for fine-
tuning was generally lower than that for feature-extractor, in both the training
and validation phases (see boxplots C.19e-C.19h). These differenes were statisti-
cally significant except for the not pre-trained fine-tuning vs. feature extractor
comparison in the validation phase (see figure C.19f and table 4.5 test no. 6). The
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Table 4.5: Diabetic retinopathy: Network loss and accuracy comparisons.
Shown are pair-wise Wilcoxon signed-rank (Test no. 1-8) or Mann-Whitney (Test
no. 9-12) comparison tests between two catagories, where 2 of 3 variables (pre-
trained vs. not pretrained, training or validation phase, fine-tuning vs. fixed
feature extractor) were held fixed and the other varied. p-values are indicated,
where p < 0.05 (marked in bold) indicates a statistically significant difference
between the two categories.
Category p-value
Test no. A B Loss Accuracy
1 Not pretrained network/training phase/fine-tuning Pretrained network/training phase/fine-tuning 0.002 0.004
2 Not pretrained network/training phase/feature-extractor Pretrained network/training phase/feature extractor 0.301 0.642
3 Not pretrained network/validation phase/fine-tuning Pretrained network/validation phase/fine-tuning 0.002 0.003
4 Not pretrained network/validation phase/feature-extractor Pretrained network/validation phase/feature extractor 0.034 0.006
5 Not pretrained network/training phase/feature extractor Not pretrained network/training phase/fine-tuning <0.001 0.005
6 Not pretrained network/validation phase/feature extractor Not pretrained network/validation phase/fine-tuning 0.569 0.248
7 Pretrained network/training phase/feature extractor Pretrained network/training phase/fine-tuning <0.001 0.001
8 Pretrained network/validation phase/feature extractor Pretrained network/validation phase/fine-tuning 0.006 0.001
9 Not pretrained/training phase/fine-tuning Not pretrained/validation phase/fine-tuning 0.053 0.003
10 Not pretrained network/training phase/feature extractor Not pretrained network/validation phase/feature extractor 0.462 <0.001
11 Pretrained network/training phase/fine-tuning Pretrained network/vaidation phase/fune-tuning 0.220 0.146
12 Pretrained network/training phase/feature extractor Pretrained network/validation phase/feature extractor 0.084 <0.001
accuracy results showed the inverse pattern as the loss results, where the accuracy
was higher in 3 of 4 cases for fine-tuning (see table 4.2, table 4.4, table 4.5 [test
no. 5-8], and the boxplots in figure C.20e-C.20h).
(3) The last group of comparisons held the pre-training vs. not pre-training vari-
able fixed and the fine-tuning vs. feature extractor variable fixed, while evaluating
for a difference between the training and validation phases. As indicated in table
4.5 there were no statistically differences for pair-wise comparisons between train-
ing and validation losses while holding the pre-trained/not pre-trained and fine-
tuning/feature extractor variables fixed. Moreover, the values in tables 4.2[test no.
9-12] and 4.4, and the boxplots in figure C.19i-C.19l indicate that the losses were
very similar between the pairs. Table 4.5 indicates that there was a statistically
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significant difference in accuracy between the training and validation groups for 3
of the 4 cases, with the exception (see table 4.5 test no. 11) being when the models
were pre-trained and used as fine-tuning (see figure C.20i-C.20l).
(4) Batch normalization(BN), applied to VGG-11, had mixed results. In the not
pre-trained cases, the loss increased and the accuracy decreased compared to VGG
withouth BN. In the pre-trained cases, the loss decreased and the accuracy in-
creased in 3 of 4 cases (the exception being training accuracy as fixed feature
extractor). In the pretrained, fine-tuning case validation accuracy substantially
increased by 6.53%, and was comparable in accuracy to VGG-19 without BN.
To evaluate for under- or over-fitting of the networks, the training to valida-
tion loss ratios were tabulated (table 4.6) and plotted (figure 4.1). The following
patterns were observed:
• AlexNet had a ratio near 1, across the type of training and fine-tuning vs.
fixed feature extractor mode.
• The DenseNet variants had ratios <1 when not pretrained, indicating these
networks have higher validation loss than training loss and may be overfit-
ting. However, when pretrained their ratios increased to >1, implying that
overfitting is not likely present.
• Inception v3 showed the same pattern whether it was pretrained or not pre-
trained: the fine-tuning ratios were <1, implying over-fitting, while the fixed
feature extractor ratios were >1.
• The ResNet variants showed differing ratios: not pre-trained fine-tuning ra-
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tios were all <1, while pretrained fine-tuning were >1, execept for ResNet-
101 and ResNet-152. The ResNet variants showed mixed ratios (table 4.6)
as fixed feature extractors. ResNet-101 suffered a high validation loss when
pre-trained as a fixed feature extractor, leading to an outlier ratio of 0.274.
• The VGG variants had ratios >1 across the combinations of pretrained or not
pretrained and fine-tuning or fixed feature extractor, implying these networks
were not over-fitting.
• When networks were not-pretrained and in fine-tuning mode, 10/16 (62.5%)
had ratios <1.
• When networks were not-pretrained and in fixed feature extractor mode,
6/16 (37.5%) had ratios <1.
• When networks were pretrained and in fine-tuning mode, 3/16 (18.75%) had
ratios <1.
• When networks were pretrained and in fixed feature extrator mode, 4/16
(25%) had ratios <1.
Five of the 16 networks were selected for further evaluation with the test
dataset. AlexNet and Inception v3 were selected along with one each of the “best”
variants of ResNet, DenseNet, and VGG. ResNet-18 was selected because it had
comparable accuracy (while minimizing complexity) to the other ResNet variants
(table 4.2) and a ratio near 1 when pretrained in fine-tuning mode. DenseNet-161
had highest accuracy when pretrained and in fine-tuning mode (table 4.2) and had
a ratio >1 with these parameters. Lastly, VGG-19 was near the top in validation
accuracy when pretrained and in fine-tuning mode (table 4.2) and had a ratio >1.
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Table 4.6: Diabetic retinopathy: Network training to validation ratio
statistics. Shown are the training to validation ratios for each network, grouped
by pre-trained vs. not-pretrained network, training vs. validation phase, and
whether the network was used in fine-tuning or fixed feature extrator mode.
Not-Pretrained Pre-Trained
Network Fine Feature Fine Feature
Tuning Extractor Tuning Extractor
AlexNet 1.004(0.005) 1.004(0.007) 1.019(0.011) 1.168(0.093)
DenseNet-121 0.823(0.156) 0.938(0.058) 1.019(1.019) 1.009(0.095)
DenseNet-161 0.789(0.150) 0.845(0.101) 1.024(0.060) 1.013(0.080)
DenseNet-169 0.802(0.180) 0.802(0.180) 1.015(0.065) 1.055(0.083)
DenseNet-201 0.691(0.261) 0.857(0.125) 1.017(0.059) 1.066(0.050)
Inception-v3 0.922(0.102) 1.032(0.138) 0.962(0.055) 1.130(0.054)
ResNet-18 0.998(0.010) 0.974(0.082) 1.016(0.047) 0.988(0.088)
ResNet-34 0.976(0.043) 0.974(0.082) 1.005(0.062) 1.034(0.079)
ResNet-50 0.743(0.260) 1.244(0.301) 1.016(0.044) 0.947(0.134)
ResNet-101 0.759(0.123) 1.119(0.255) 0.912(0.174) 0.274(0.119)
ResNet-152 0.701(0.117) 1.096(0.253) 0.836(0.216) 0.943(0.122)
VGG-11 1.006(0.005) 1.011(0.005) 1.025(0.032) 1.341(0.159)
VGG-11bn 1.010(0.027) 2.220(0.483) 1.031(0.023) 1.305(0.137)
VGG-13 1.005(0.005) 1.010(0.007) 1.058(0.023) 1.223(0.190)
VGG-16 1.005(0.005) 1.010(0.003) 1.032(0.032) 1.252(0.218)
VGG-19 1.005(0.005) 1.011(0.003) 1.026(0.030) 1.230(0.156)
Accuracy of these 5 networks (pretrained) as fixed feature extractors or in fine-
tuning mode when run with the test dataset is shown in table 4.7. With fixed
feature extractor, 4 of 5 networks had accuracy around 72-73%, while DenseNet-
161 had lower accuracy around 68%. With fine-tuning, AlexNet and Inception v3
had about 3-4% lower accuracy than the other 3 networks. DenseNet-161, ResNet-
18, and VGG-19 had comparable accuracy around 76-77%.
Quadratic weighted kappa was tabulated for each of the 5 networks (table 4.8).
In fixed feature extractor mode, Inception v3 and VGG-19 showed poor level of
agreement, while AlexNet, DenseNet-161, and ResNet-18 showed fair agreement.
In fine-tuning mode, AlexNet and Inception v3 showed poor level of agreement,
while DenseNet-161, ResNet-18, and VGG-19 showed moderate level of agreement.
Sensitivity and specificity were tabulated for each of the 5 networks (table
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Table 4.7: Diabetic retinopathy: Network Test Accuracy. Accuracy(%) is
indicated for the specified networks (all pre-trained) for fixed feature extractor and
fine tuning modes.
Network Fixed Feature Extractor Fine-Tuning
AlexNet 72.2 73.6
DenseNet-161 68.3 77.5
Inception-v3 73.7 73.8
ResNet-18 72.8 76.1
VGG-19 73.2 77.4
Table 4.8: Diabetic retinopathy: Network Test Quadratic Weighted
Kappa. Quadratic weighted kappa values are indicated for the specified net-
works (all pre-trained) for fixed feature extractor and fine tuning modes. A gen-
erally agreed upon scale is: <0.20(Poor), 0.21-0.40(Fair), 0.41-0.60(Moderate),
0.61-0.80(Good), and 0.81-1.00(Very good).
Network Fixed Feature Extractor Fine-Tuning
AlexNet 0.21 0.18
DenseNet-161 0.32 0.55
Inception-v3 0.005 0.15
ResNet-18 0.23 0.47
VGG-19 0.16 0.56
4.9). Since sensitivity and specificity are based on a binary classification, they
were calculated in two ways: (1) for “any DR,” where the binary classification was
Class 0 vs. any level of DR (Class 1, 2, 3, or 4); and (2) “referable DR,”1 where
the binary classification was non-referable (Class 0 or 1) vs. referable (Class 2, 3,
or 4). Table 4.9 shows that:
• Sensitivity was generally low for all the networks whether fine-tuning vs.
fixed feature extractor.
• Sensitivity was in all cases higher for fine-tuning compared to fixed feature
extractor. For VGG-19, it was substantially higher (57.2% vs. 8.3%).
1See [26] for definition of “referable DR.”
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• The highest sensitivity was achieved by VGG-19 (fine-tuning).
• Inception v3 showed poor sensitivity.
• Specificity was generally high (>94%) for all the networks (fine-tuning).
Table 4.9: Diabetic retinopathy: Network Test Sensitivity and Speci-
ficity. Sensitivity(%) and specificity(%) values are indicated for the specified net-
works (all pre-trained) for fixed feature extractor and fine tuning modes. Any DR
indicates any level of diabetic retinopathy, referable DR indicates referable dia-
betic retinopathy, which is class 2 or higher (i.e., moderate diabetic retinopathy or
worse).
Fixed Feature Extractor Fine-tuning
Any DR Referable DR Any DR Referable DR
Network Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity Sensitivity Specificity
AlexNet 10.8 96.6 13.7 96.7 12.1 97.3 15.7 97.3
DenseNet-161 34.6 85.5 41.2 85.3 41.6 95.1 54.1 94.9
Inception-v3 3.0 99.9 4.0 99.9 10.5 97.6 13.3 97.8
ResNet-18 13.7 96.1 17.3 96.2 33.9 95.4 44.3 95.3
VGG-19 6.7 98.2 8.3 98.4 44.9 94.4 57.2 94.1
A selected subset of networks (DenseNet-161, Inception v3, ResNet-18, and
VGG-19) were re-run (as pretrained, fine-tuning) for 50 epochs. Their loss and
accuracy curves are plotted in figure 4.2. These plots show that the loss and
accuracy begin to converge at around 10 epochs for these networks and there is
minimal improvement in loss or accuracy past 10 epochs.
The effect of image pre-processing (see pre-processing methodology in chap-
ter 3) was analyzed for selected networks (AlexNet, DenseNet-161, Inception v3,
ResNet-18, and VGG-19). Networks were pre-trained and used for fine-tuning and
run for 10 epochs. Table 4.10 shows there was minimal improvement of loss and
accuracy for AlexNet, DenseNet-161 or ResNet-18. The validation accuracy for
VGG-19 decreased very slightly (0.66%). For Inception v3, there was a significant
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improvement in validation accuracy (6%).
Table 4.10: Diabetic Retinopathy: Loss and Accuracy with image pre-
processing. Shown are the loss and accuracy for selected networks, comparing
these values between runs with and without image pre-processng. Networks were
pre-trained, run in fine-tuning mode for 10 epochs.
Loss Accuracy
Network Training Validation Training Validation
AlexNet, without pre-processing 0.7475 0.7431 0.7520 0.7579
AlexNet, with pre-processing 0.7475 0.7402 0.7524 0.7528
DenseNet-161, without pre-processing 0.6067 0.6162 0.8003 0.8038
DenseNet-161, with pre-processing 0.5808 0.5946 0.8073 0.8105
Inception v3, without pre-processing 0.6368 0.6923 0.7896 0.7368
Inception v3, with pre-processing, 0.5996 0.6401 0.8013 0.7974
ResNet-18, without pre-processing 0.6467 0.6616 0.7847 0.7952
ResNet-18, with pre-processing 0.6271 0.6177 0.7927 0.7969
VGG-19, without pre-processing 0.6055 0.5985 0.7990 0.8106
VGG-19, with pre-processing 0.5975 0.5995 0.8018 0.8040
The effect of adjusting class weights to account for class imbalance was inves-
tigated. VGG-19 (pretrained, fine-tuning) was re-run using various class-adjusted
weights specified in table 4.11. The weights were adjusted to weigh Class 0 less
than the other classes. One recommendation was to use weights corresponding to
the inverse of the class size, which is the second row in table 4.11. Other class
weights were experimented. The results indicate that adjusting the weights did
not lower the loss or increase the accuracy over equally weighted classes.
Lastly, the effect of using bilateral eye data was investigated. The rationale is
that if either of a given patient’s eye meets criteria for referal from a screening,
then the patient is referred for further evaluation. For example, if the right eye is
Class 0 and the left eye is Class 3 (severe NPDR) then the patient is referred for
further evaluation.
The Kaggle Diabetic Retinopathy data set consists of bilateral eye data. The
test dataset consists of 53,576 images from 26,788 patients, where each patient con-
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Table 4.11: Diabetic Retinopathy: VGG-19 class-weighted loss and ac-
curacy. Shown are the class-weighted loss and accuracy for VGG-19, run as
pre-trained in fine-tuning mode for 10 epochs. For comparison reference, the first
row is the result from table 4.1 where the run was for equal weights across classes.
Class-adjusted weight Loss Accuracy
Class 0 Class 1 Class 2 Class 3 Class 4 Training Validation Training Validation
1.0 1.0 1.0 1.0 1.0 0.6055 0.5985 0.7990 0.8106
0.000004 0.00045 0.0002 0.0013 0.0016 1.0820 1.0840 0.6651 0.7390
0.01 1 1 10 10 1.0917 1.0458 0.6494 0.6917
0.25 1.0 0.85 1.0 1.0 0.8698 0.8662 0.7809 0.7926
1 100 100 1000 10000 1.0913 1.0624 0.6624 0.7567
tributed a right and left eye image. To analyze if performance could be increased,
the test cases were “blended” from eye to patient level by assigning a patient level
diagnosis based on the eye with worse severity. This analysis was carried out for
VGG-19 (pre-trained, fine-tuning), which showed accuracy of 73%, sensitivity and
specificity of 66% and 90% (for referable DR), and quadratic weighted kappa of
0.58. This was a decrease of 3.4% in accuracy, an increase of 8.8% in sensitivity, a
decrease of 4.1% in specificity, and an increase of 0.02 in quadratic weighted kappa
compared to eye-level statistics.
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(a) Not pre-trained, fixed feature extractor.
(b) Not pre-trained, fine-tuning.
Figure 4.1: Diabetic Retinopathy: Network training to validation ratio
boxplots. Plotted are the training to validation ratios for each network. A ratio
<1 implies over-fitting of the network.
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(c) Pre-trained, fixed feature extractor.
(d) Pre-trained, fine-tuning.
Figure 4.1: Continued - Diabetic Retinopathy to Network training to
validation ratio boxplots. A ratio <1 implies over-fitting of the network.
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(a) Loss for ResNet-18.
(b) Accuracy for ResNet-18.
Figure 4.2: Diabetic Retinopathy: Selected networks loss and accuracy
curves over 50 epochs. Mode was set to fine-tuning and networks were pre-
trained.
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(c) Loss for Inception v3.
(d) Accuracy for Inception v3.
Figure 4.2: Continued - Diabetic Retinopathy: Selected networks loss and
accuracy curves over 50 epochs. Mode was set to fine-tuning and networks
were pre-trained.
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(e) Loss for Densenet-161.
(f) Accuracy for Densenet-161.
Figure 4.2: Continued - Diabetic Retinopathy: Selected networks loss and
accuracy curves over 50 epochs. Mode was set to fine-tuning and networks
were pre-trained.
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(g) Loss for VGG-19.
(h) Accuracy for VGG-19.
Figure 4.2: Continued - Diabetic Retinopathy: Selected networks loss and
accuracy curves over 50 epochs. Mode was set to fine-tuning and networks
were pre-trained.
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Chapter 5
Discussion
This report detailed the results of a transfer learning evaluation for classifi-
cation of diabetic retinopathy by digital fundus photography. Prior reports (see
chapter 2) have investigated select DNNs, such as Inception v3 or custom CNNs.
However, to the best of my knowledge, no prior work has systematically investi-
gated the performance of the full suite of PyTorch torchvision models.
In this study, transfer learning techniques were applied to AlexNet, Incep-
tion v3, and the variants of DenseNet, ResNet and VGG for classification of di-
abetic retinopathy by digital fundus photographs of the retina. The largest pub-
lically available dataset (as of the time of this report) from the Kaggle Diabetic
Retinopathy Detection competition was utilized for training, validation, and test-
ing. This dataset comprises just over 88K retinal fundus images and was acquired
in a screening setting, where the images were taken under a variety of conditions.
The 16 DNNs under evaluation were run in 4 configurations: in a not pre-
trained mode to establish a baseline for comparison, and then with the pre-trained
configuration (i.e. network weights established previously from the ImageNet
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dataset). Within each mode, the networks were run in configuration of either
a fixed-feature extractor (i.e. “training the top layer”) or in fine-tuning mode,
whereby the network is retrained with the data from the transfer domain. Which
of these modes of training yields higher accuracy is unclear since prior reports do
not detail which methodology has been utilized, although prior work likely used
the “training the top layer approach.” The rationale for this approach is that the
torchvision models, such as ResNet, have been trained on millions of images, and
thus can be sucessfully transferred to detect lower level features (e.g. edge corners)
that are agnostic to a particular target domain. Presumably, then, retraining of
the top layer to another domain while freezing the lower layers should yield good
accuracy. The key findings from this study are:
(1) Pre-trained networks, in general, performed better than not pre-trained (con-
sidered baseline models in this study), as indicated by lower loss and higher accu-
racy. This was confirmed at the level of each particular DNN (tables 4.1 and 4.2,
figures C.3-C.18) and when the networks were aggregated for analysis (tables 4.3,
4.4, 4.5[Test no. 1-4], figures C.19, C.20). This finding is expected, since networks
that were evaluated as pre-trained on the very large ImageNet dataset (on order
of millions of images) should have better ability to detect low level features, and
in turn to result in better performance at the higher layers, compared to the same
network trained on the relatively smaller Kaggle dataset (on order of tens of thou-
sands of images).
(2) Except for VGG, adding layers to a particular network generally did not im-
prove performance. In particular, the loss (across pretrained vs. not-pretrained and
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fine-tuning vs. fixed feature extractor combinations) stayed stable for the DenseNet
variants as the number of layers increased (table 4.1, figure C.1). The loss for the
ResNet variants mostly stayed stable or slightly increased, except ResNet-101,
which showed a significant increase in loss in one combination (pretrained, valida-
tion phase, feature extractor). There was a slight increase in loss from VGG-11 to
the more complex VGG variants, except for the pretrained, validation phase, fine
tuning combination where loss decreased from VGG-11 to VGG-19. The accuracy
data showed that adding layers in the networks did not substantially change the
accuracy for DenseNet or ResNet (table 4.2, figure C.2). The (pretrained) valida-
tion accuracy for VGG (fine-tuning) improved substantially from VGG-11 (73.5%)
to VGG-13 (80.8%), with minimal change with VGG-16 or VGG-19. On the other
hand, the accuracy for (pretrained) VGG (feature extractor) did not change sub-
stantially with more layers.
(3) The network training to validation ratios showed that when not pre-trained,
most of the networks had ratios near or >1, except for the DenseNet variants, and
ResNet-50, -101, and -152 when evaluated in fine-tuning mode (table 4.6, figure
4.1). This may imply that DenseNet and those particular ResNet variants were
overfitting. When the networks were configured as pre-trained, the ratios were all
near 1 or >1 for all the networks, except ResNet-152. There was a deviation in
validation loss for ResNet-101 as a feature extractor (table 4.1), which caused an
outlier ratio. In general, however, the ratio data suggests that most of the models
were not overfitting when pre-trained (either fixed feature extractor or fine-tuning)
and that those models that may have been overfitting when not pretrained (the
DenseNet variants) were not overfitting when pretrained.
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With the result of higher performance of pretrained over not pretrained networks
established, the remaining analysis explored pretrained networks only, and in par-
ticular a subset of candidate networks for further analysis (AlexNet, DenseNet-161,
Inception v3, ResNet-18, and VGG-19). Further key findings were:
(4) Most of the networks in this subset showed >72% accuracy, with the exception
of DenseNet-161 (68.3%). This is inline with the >70% accuracy (interpreted as
100% - Top-1 error in table 1.1) of these networks (excluding AlexNet) reported on
ImageNet. The accuracy of each network was higher in fine-tuning mode compared
to fixed feature extractor (range of difference 0.1-9.2%), indicating that these net-
works had comparable (AlexNet, Inception v3) or in some cases (DenseNet-161,
ResNet-18, and VGG-19) significantly higher accuracy in fine-tuning mode (table
4.7). DenseNet-161 and VGG-19 achieved the highest accuracies (77.5 and 77.4%,
respectively) amongst the networks when fine-tuned.
(5) The quadratic weighted kappa was poor in 2 cases (Inception v3, VGG-19)
and fair in 3 cases (AlexNet, DenseNet-161, ResNet-18) in fixed feature extractor
mode (table 4.8). In fine-tuning mode, the quadratic weighted kappa was poor in 2
cases (AlexNet, Inception v3) and moderate in 3 cases (DenseNet-161, ResNet-18,
VGG-19). As in the accuracy results, DenseNet-161 and VGG-19 achieved the
highest two kappa scores.
(6) The sensitivity of this subset of networks for DR detection was generally poor
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or fair (table 4.9). The sensitivity of each network was much higher when in
fine-tuning compared to fixed feature extractor mode, in some cases substantially
higher (ResNet-18 and VGG-19). These relatively low sensitivity values indicate
that there was a high proportion of false negatives. In the case of the “any DR”
binary classification, this implied a high number of cases were predicted to be Class
0 by the network but identified as diseased by the ground truth. In the case of
the “referable DR” binary classification, this implied that the network predicted
cases to be non-referable when in fact the ground truth labeled them as referable.
The issue of poor sensitivity and misclassification is explored further below. Com-
paring the sensitivity when the fine-tuning or fixed feature extractor variable was
kept the same showed that the sensitivity was (as expected) higher for referable
DR compared to any DR, but not substantially so.
(7) The specificity of this subset of networks for DR detection was generally high:
>94% for all networks (fine-tuning or fixed feature extractor), except for DenseNet-
161, which achieved about 85% specificity with fixed feature extractor (table 4.9).
These results indicate that the networks generally were able to correctly identifiy
no DR (or non-referable) cases very well, with a small portion of false positives.
Taken together, these finding indicate that pretained networks performed bet-
ter than not-pretrained networks, and that the networks generally performed bet-
ter when fine-tuned rather than with the fixed feature extractor configuration.
Adding layers to the DenseNet and ResNet networks generally did not enhance
performance, but there was a significant boost from VGG-11 to the other VGG
variants. The ratio data suggests that the networks were generally not overfitting
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when pretrained.
The accuracy of the subset of networks selected to be evaluated with the test
data (AlexNet, DenseNet-161, Inception v3, ResNet-18, and VGG-19), showed
similar accuracy when used in fine-tuning mode (range 73.6-77.5% accuracy). The
accuracy was higher for fine-tuning compared to fixed feature extractor in 4 of
5 cases (AlexNet, DenseNet-161, ResNet-18, and VGG-19), and stayed stable for
Inception v3.
The quadratic weighted kappa results indicate that the networks generally had
poor to fair level of agreement in fixed feature extractor mode. Although the kappa
values improved with fine-tuning, the highest kappa value (0.56 for VGG-19), still
indicated only moderate level of agreement. Of note, the metric used by the Kag-
gle Diabetic Retinopathy Detection competition was the quadratic weighted kappa
rather than accuracy, with the two top submissions receiving scores of 0.84957 and
0.84478, respectively.
Both of those submissions used techniques (random forest, resampling) to ad-
dress the class imbalance issue with this dataset, specifically that a large portion
of the dataset is labeled as Class 0. In this analysis, the class weights were ad-
justed for the VGG-19 network (pretrained, fine-tuning), however no improvement
in accuracy was observed (table 4.11). Interestingly, Pratt et al. [37] recognized
the risk of class imbalance overfitting, and described their strategy as “for every
batch loaded for back-propagation, the class-weights were updated with a ratio
respective to how many images in the training batch were classified as having no
signs of DR. This reduced the risk of over-fitting to a certain class to be greatly
reduced.”
It is unclear how much their technique reduced the risk, since no comparative
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data without this method is provided in their report. However, they reported that
their final trained network achieved 95% specificity, 75% accuracy and 30% sensi-
tivity (based on an “any DR” classification scheme). In this study, the best results
were achieved by VGG-19 (with no class weight adjustments), which showed 77.4%
accuracy, 44.9% sensitivity, and 94.4% specificity (“any DR,” when pretrained and
fine-tuning). Thus, VGG-19’s accuracy and specificity (without class weighted ad-
justment) was comparable to that of the CNN by Pratt et al. while the sensitivity
of VGG-19 was about 15% higher. It should be noted that Pratt et al. did not
report a kappa statistic in their paper. Furthermore, it is unclear how much of an
effect the class imbalance strategies employed by the top two Kaggle submissions
had since scores were only provided on the final overall models. Further study of
the role of class imbalance and strategies to compensate for it are needed.
Another strategy that the top Kaggle submission and Pratt et al. used was im-
age pre-processing. The second place Kaggle submission stated that “we crop away
all background and resize the images to squares of 128, 256 and 512 pixel” but did
not use other image pre-processing. Pratt et al. described a “colour normalisation”
scheme, while the top Kaggle submission used an image pre-processing technique
detailed in chapter 3. As in the case of class imbalance above, it is unclear how
much the image pre-processing increased performance, as results for only the final
model are provided. In this report, the effect of image pre-processing (utilizing the
same methodology as the top Kaggle submission) was analyzed (table 4.10) for a
subset of networks and showed that performance improved modestly (6%) for only
1 of the 5 networks (Inception v3).
Lastly, an examination of the possible sources of error is instructive. For VGG-
19 (pre-trained, fine-tuning) the 53,576 predictions consisted of 6,311 (11.8%) true
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positives, 37,306 (69.6%) true negatives, 2,227 (4.2%) false positives, and 7,732
(14.4%) false negatives. As indicated by the high specificity, we observe that there
was a relatively small percentage of false positives. The confusion matrix1 in fig-
ure 5.1 shows that amongst the 2,227 false positives, 2,129 (95.6%) occured when
VGG-19 predicted class 2 (moderate NPDR) when ground truth was labeled as
class 0.
Figure 5.1: Confusion Matrix for VGG-19.
The author of this report, a board-certified ophthalmologist, reviewed a ran-
1See https://en.wikipedia.org/wiki/Confusion_matrix
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dom sample of 50 cases among the 2,129 class 2/class 0 misclassifications. In that
random sample, 18 (36%) were false positives because the eye had drusen (deposits
typically found in age-related macular degeneration, not associated with diabetic
retinopathy), but no diabetic retinopathy. Presumably, the neural network de-
tected the drusen incorrectly as retinal hemorrhages or exudates and misclassified
the diagnosis. Another 18 (36%) cases were due to “smudge” artifacts from the
camera, which the network likely identified as diabetic findings, but were correctly
labeled by ground truth as class 0. Six (12%) cases had poor lighting/artifact, and
presumably the neural network identified dark regions as areas of disease. Three
(6%) cases had retinal scars (not due to diabetes) that were likely identified as
diabetic findings by the network. Three (6%) cases had a true retinal hemorrhage,
and thus were misclassified by ground truth as normal. Two cases (4%) had suf-
ficient quality (no artifact or lighting issues) and no retinal pathology, and were
thus true errors by the network. Figure 5.2 shows representative examples from
each type of misclassification.
It is unclear what triggered the network to misclassify the last two particular
cases (true errors), but this type of true error represented a small (4%) percent-
age of the random sample. Cases where other types of retinal pathology (drusen,
retinal scars) would lead to referal for evaluation would be indicated anyway if the
photo was reviewed manually. Poor lighting and camera artifact are troublesome
issues and represented a non-trival percentage (48%) of the random sample. A
strategy to deal with these issues is identify the poor quality photo at the time
of aquisition, either manually or by deep learning techniques[39] and attempt to
re-image the patient or refer if still indequate. While such sources of false positives
are troublesome in terms of adding extra cases to manually screen, from a clini-
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cal standpoint it is better to refer potentially normal cases for further evaluation
rather than miss potential disease.
The confusion matrix in figure 5.1 shows that amongst the 7,732 false negatives,
the majority occured when the ground truth label was class 1 (3,358 cases, 43.4%)
or class 2 (3,975 cases, 51.4%), with a smaller proportion when ground truth was
class 3 (160 cases, 2.1%) or class 4 (239 cases, 3.1%). A random sample of 100
false negative cases were selected for further review, 25 images from each class.
Table 5.1 indicates that in total, 42% of the random sample were false nega-
tives where VGG predicted Class 0, but the image did show features of diabetic
retinopathy. 27% of images were of poor quality, and likely should have not been
labeled by ground truth (i.e. excluded). 31% of images were labeled incorrectly,
and either were normal or had other retinal features (e.g. drusen) but not diabetic
retinopathy. Examples of misclassifications are shown in figure 5.3.
Table 5.1: Diabetic retinopathy: VGG-19 False Negatives Listed is a break-
down of the cause of a false negative classification for 100 random images classified
as false negatives. The VGG-19 predictions were all Class 0. Each table entry
listed the number of cases.
Ground Truth Label Actual FN Image Poor Quality Ground Truth Label Error
Class 1 8 6 11
Class 2 7 7 11
Class 3 12 7 6
Class 4 15 7 3
Totals 42(42%) 27(27%) 31(31%)
Upon detailed review, it appears that cause of acutal false negatives were due
to the network missing subtle features, such as very small retinal hemorrhages or
exudates, especially when they are located in areas of the photo with low light
or contrast. Additionally, the network may have not been trained on enough
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images of PDR showing vitreous hemorrhage or PDR treated with laser, and thus
misclassified these cases as Class 0. Further study with a larger training and
validation dataset of such relatively uncommon cases would be beneficial. It also
appears that image pre-processing may have not helped to “enhance” very small
features such as microaneurysms in low contrast regions of an image. This may
represent an inherit limitation of DNNs in diabetic retinopathy detection, and
a particular scenario where a human’s ability to detect such subtle features still
outperforms the network’s. Further study of image pre-processing techniques or
other network enhancements to detect such small features is warranted.
The finding that a non-trivial percentage (31%) of the random images classified
as false negatives were due to ground truth label errors may imply that the accuracy
and sensitivity were underestimated. Possible sources of error could be that ground
truth readers defaulted to label a case as having DR when image quality was
inadequate for diagnosis, or since the ground truth labels were human generated,
there always will exist some level of error.
Moreover, Pratt et al. [37] noted “an associated issue identified, which was
certified by a clinician, was that by national UK standards around over 10% of
the images in our dataset[Kaggle] are deemed ungradable. These images were
defined a class on the basis of having at least a certain level of DR. This could
have severely hindered our results as the images are misclassified for both training
and validation.” Gulshan et al. [36] achieved a mich higher sensitivity using their
dataset with the Inception v3 network, but it should be noted that a large number
of ophthalmologists or ophthalmology trainees graded their datasets, highlighting
that an accurately labeled ground truth dataset is critical and may shift accuracy
and sensitivity results of the DNN.
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A limitation of this study was access to a large dataset of labeled retinal images
(the Kaggle dataset being the largest in the public domain at this time). Further
study with the smaller public Messidor-2 dataset may be informative. As a greater
number of large datasets become available in the public domain, further research in
the performance of transfer learning for diabetic retinopathy using retinal fundus
photography will be of practical importance to validate this methodology as a
screening technique.
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(a) Drusen (yellow deposits on the left side of image)
may have been misclassified as DR feature.
(b) “Smudges” due to camera artifact likely may have
been misclassified as DR feature.
Figure 5.2: Diabetic Retinopathy: examples of false positives.
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(c) Image was mis-labeled by ground truth. Has a retinal
hemorrhage, indicating presence of DR.
(d) Image has a retinal scar at the top, unrelated to
diabetes, and was likely misclassified as a DR feature.
Figure 5.2: Continued - Diabetic Retinopathy: examples of false positives.
73
(e) Image was labled correctly as class 0 by ground truth.
The network misclassified this image as class 2 (unclear
why).
Figure 5.2: Continued - Diabetic Retinopathy: examples of false positives.
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(a) The network missed very small microaneurysms
(small red dots) present in the image, indicating pres-
ence of DR.
(b) Likely a mislabel by ground truth. Drusen (small
yellow dots) are present, but no features of DR are evi-
dent.
Figure 5.3: Diabetic Retinopathy: examples of false negatives.
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(c) An example of a poor quality image, labeled as having
DR by ground truth, likely should have been excluded.
(d) The network missed subtle microaneurysms and ex-
udates present, indicated DR.
Figure 5.3: Continued - Diabetic Retinopathy: examples of false negatives.
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(e) The image has a vitreous hemorrhage, indicating
PDR.
(f) The network missed the laser scars, indicating PDR.
Figure 5.3: Continued - Diabetic Retinopathy: examples of false negatives.
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Part III
Transfer Learning for
Classification of Diabetic Macular
Edema, Choroidal
Neovascularization and Drusen by
Optical Coherence Tomography
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Chapter 6
Background
This part of the report analyzes the inter-disease classification performance
of a suite of DNNs. The input images were JPEG photos of optical coherence
tomography (OCT) scans through the macula. The DNNs were trained on photos
showing 4 types of classes: (1) no disease (normal); (2) diabetic macular edema
(DME); (3) choroidal neovascularization (CNV); or (4) drusen. CNV and drusen
are two features associated with age-related macular degeneration (ARMD). OCT
imaging is briefly reviewed next and in the following sections each of these clinical
entities is briefly reviewed.
6.1 Optical Coherence Tomography
Optical Coherence Tomography (OCT) is a non-invasive imaging technique that
provides high resolution cross sections of the retina with an axial resolution in the
5-7 µm range (see figure 6.2 for an example of a normal OCT)[41]. OCT provides
histological level detail of the retina. OCT employs light from a broadband light
source, which is divided into a reference and a sample beam, to obtain a reflectivity
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versus depth profile of the retina. The light waves that are backscattered from the
retina, interfere with the reference beam, and this interference pattern is used to
measure the light echoes versus the depth profile of the tissue in vivo[42][43]. For
technical details of OCT, the reader is referred to [44].
OCT is used extensively for imaging the macula and has become pivotal for
diagnosis of retinal diseases such as DME and ARMD. It is estimated that 30
million OCT studies are done worldwide per year[45], and that figure is projected
to continue growing with increasing prevalence of disease such as diabeties and
macular degeneration. With rising demand for OCT imaging, there will likely
be challenges keeping up with this demand for human based interpretation of
images. Deep learning methods, discussed below, could be a promising technology
to address this need.
Figure 6.1: Example of a Normal Optical Coherence Tomography Image. Nor-
mal anatomy of the central macula. NFL, nerve fiber layer; GCL, ganglion cell
layer; IPL, inner plexiform layer; INL, inner nuclear layer; OPL, outer plexiform
layer; ONL, outer nuclear layer; ELM, external limiting membrane; IS/OS, in-
ner segment/outer segment junction; RPE, retinal pigment epithelium. Repro-
duced from https://www.aao.org/young-ophthalmologists/yo-info/articl
e/4-tips-assessing-macular-oct-scan.
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6.2 Diabetic Macular Edema
An overview of diabetic retinopathy (DR) is provided in chapter 2. Diabetic
macular edema (DME) is a form of DR that involves the macula, the center of
the retina.1 Depending on the location of the DME and its chronicity, permanent
vision loss can ensue. DME is a clinical diagnosis based upon a steroscopic dilated
retinal fundus examination. The clinical diagnosis recognizes two forms of DME:
clinically significant macular edema (CSME) and non-CSME. Criteria for CSME,
described in [11], include any of the following:
• Thickening of the retina at or within 500 µm of the center of the macula.
• Hard exudates at or within 500 µm of the center of the macula, when as-
sociated with adjacent retinal thickening. (This criteria does not apply to
residual hard exudates that remain after successful treatment of prior retinal
thickening.)
• A zone or zones of retinal thickening one disc area or larger, where any
portion of the thickening is within one disc diameter of the center of the
macula
With the advent of OCT and intravitreal anti-vascular endothelial growth fac-
tor (VEGF) treatment, it has now become more appropriate to subdivide DME
according to involvement at the center of the macula, because the risk of visual
loss and the need for treatment is greater when the center is involved.
OCT has become a pivotal imaging technology for ophthalmic imaging. How-
ever, the American Academy of Ophthalmology’s preferred practice pattern does
1Portions of this section courtesy of Diabetic Retinopathy Preferred Practice Pattern
(2017)[11].
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not recommend OCT to screen a patient with no or minimal diabetic retinopathy
(figure 6.2). As such, OCT, unlike digital fundus photography, is not currently
recommended for population wide screening. Rather, OCT’s current role in DME
is to quantify the progression of DME or response to treatment, in patients with
an established history of DME. Stereoscopic fundus photography is useful to doc-
ument DME, but is not readily used for screening purposes, and because of the
readier availability of OCT and ability to quantify DME over steroscopic imaging,
OCT is generally utlilized in favor of steroscopic imaging. Non-stereoscopic fundus
imaging, taken in a screening setting, can possibily detect DME based upon the
presence of hard exudates, which are sometimes associated with macular edema
(figure 6.3).
Figure 6.2: American Academy of Ophthalmology guidelines for use of optical
coherence tomography for diabetic retinopathy, reproduced from [11].
6.3 Age-related Macular Degeneration
Age-related macular degeneration (ARMD) is a disorder of the macula, the
center of the retina responsible for central visual acuity. Patient are typically 50
years of age or older. ARMD is a leading cause of severe, irreversible vision impair-
ment in developed countries. The prevalence of ARMD varies across ethnicity and
age, with increased prevalence in Caucasian and older patients. Estimates suggest
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that the 1.75 million individuals affected by advanced ARMD in at least one eye
are expected to increase to nearly 3 million by year 2020. ARMD is divided into
a “dry” form (about 80% of cases) and a “wet” form (about 20% of cases), which
is responsible for nearly 90% of the severe visual acuity loss. Effective treatments
currently exist for the “wet” form using anti-VEGF therapy, as well as anti-oxidant
therapy to slow the progression of the “dry” form.
A rigorous classification system based on the Age-Related Eye Disease Study
was created. It is based on several morphological features and the reader is referred
to [40] for details. This study investigated two particular morphological features
associated with ARMD, drusen and choroidal neovascularization, discussed in fur-
ther detail below.
6.3.1 Choroidal Neovascularization
Choroidal neovascularization (CNV) occurs when blood vessels from the chori-
ocapillaris (the layer below the retina) perforate through Bruch’s membrane (a
barrier between the retinal pigment epithelium and the choriocapillaris), leading
to hemorrhage underneath the retinal pigment epithelium or the retina. The hem-
orrhage can lead to profound vision loss that may be irreversible without prompt
treatment.
CNV can be detected by clinical examination and its presence confirmed by
fluorescein angiography. It can also be detected on OCT (figure 6.4). CNV is
associated with the “wet” type of macular degeneration, but it not exclusively
found in this disease as it could be seen in other retinal diseases such as high my-
opia and histoplasmosis. Recognition of CNV, such as with OCT, is important for
diagnostic and therapeutic purposes.
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6.3.2 Drusen
Drusen are yellow lesions at the level of the basement membrane of the retinal
pigment epithelium. Though drusen are the hallmark of ARMD, they can be
seen in other retinal conditions such as dominant drusen. Drusen are diagnosed
by clinical examination and can be confirmed on OCT imaging (figure 6.5). It
is important to recognize drusen for diagnostic purposes and then to characterize
them by size (small, medium, or large) and morphology (soft or hard) for prognostic
purposes.
6.4 Prior work on OCT-based classification
Deep learning (DL) is a promising technology to automate classification of OCT
images. Prior techniques that relied on pre-DL methodologies, such as using hand
crafted segmentation, will not be reviewed here. This section briefly reviews prior
DL-based work on OCT-based classification for DME, CNV and drusen (in the
context of ARMD).
Alsaih et al. evaluated machine learning techniques for DME classification on
OCT images[46]. They used extraction of histogram of oriented gradients and
local binary pattern (LBP) features within a multiresolution approach as well as
principal component analysis (PCA) and bag of words (BoW) representations, and
found that their best results led to a sensitivity and specificity of 87.5 and 87.5%,
respectively.
Kamble et al. [47] finetuned Inception-Resnet-v2[48] on the publicly avail-
able data set of the Singapore Eye Research Institute (SERI). They reported that
they achieved 100% classification accuracy (on DME images from OCT) with the
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Inception-Resnet-v2 model using a leave-one-out crossvalidation strategy.
Venhuizen et al. evaluated a machine learning algorithm that automatically
grades ARMD severity stages from OCT scans[49]. Their algorithm was built
around the Bag of Words (BoW) approach. They report that their system achieved
an area under the ROC curve of 0.980 with a sensitivity of 98.2% at a specificity
of 91.2%. They state that this compares favorably with the performance of human
observers who achieved sensitivities of 97.0% and 99.4% at specificities of 89.7%
and 87.2%, respectively. Moreover, they report a good level of agreement with
the reference was obtained (κ = 0.713) and was in concordance with the human
observers (κ = 0.775 and κ = 0.755, respectively).
A landmark study by Kermany et al. [50] utilized transfer learning applied to
the largest (∼100K images) publically available dataset for classification of DME,
CNV, and drusen. They report using Tensorflow adapted with an Inception V3
architecture pretrained on the ImageNet dataset, and the convolutional layers were
frozen and used as fixed feature extractors. In a multi-class comparison between
CNV, DME, drusen, and normal, they report that they achieved an accuracy of
96.6%, with a sensitivity of 97.8%, a specificity of 97.4%, and a weighted error of
6.6%.
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Figure 6.3: Representative color fundus photo (top) and OCT (bottom) of Diabetic
Macular Edema, reproduced from https://www.aao.org/eyenet/article/dia
betic-macular-edema-personalizing-treatment. The photo shows a circinate
ring of hard exudates (yellow deposits), wich may be associated with macular
edema.
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Figure 6.4: Representative OCT of CNV, reproduced from https://iovs.arvoj
ournals.org/article.aspx?articleid=2150855
Figure 6.5: Representative OCT of Drusen. Shown are a color photo (top) of the
fundus (back of the eye) and optical coherence tomography (OCT) scan (bottom)
in a patient with ARMD, showing multiple large drusen (lipid and fatty protein
deposits). Reproduced from https://www.masseyeandear.org/news/press-rel
eases/2016/02/patients-with-high-risk-macular-degeneration-show-imp
rovement-with-high-dose-statin-treatment
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Chapter 7
Methods
Methodology similar to that in part II was used in this part of the report.
The dataset used in this part of the report was obtained from [50].1 This dataset
consists of 109,309 OCT JPEG images, taken through the macular center, from pa-
tients with: no retinal disease (Class 0), DME (Class 1), CNV (Class 2), and drusen
(Class 3). The dataset provider partitioned the images into 108,309 for training
and 1,000 for testing. In this report, the author randomly selected 10,831(10%) of
the 108,309 images for a validation dataset, leaving 97,478(90%) for training. The
distribution of the dataset, broken down by training, validation, and test data, and
by classification category is listed in table 7.1. Examples of each class are shown
in figure 7.1.
In this part of the report, the following networks were selected for baseline
analysis: AlexNet, DensetNet-121, Inception v3, Resnet-18, and VGG-11. Each
network was run pre-trained, in fixed-feature extractor and fine-tuning mode (see
3.2 for details about these configurations). The same settings as in 3.2 were used as
1Available at https://data.mendeley.com/datasets/rscbjbr9sj/2
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Table 7.1: Distribution of labels across training, validation, and test sets for the
OCT classification dataset.
Class 0 Class 1 Class 2 Class 3 Total
Training 46,026(47.2%) 10,213(10.5%) 33,485(34.3%) 7,754(8.0%) 97,478
Validation 5,114(47.2%) 1,135(10.5%) 3,720(34.3%) 862(8.0) 10,831
Test 250(25%) 250(25%) 250(25%) 250(25%) 1,000
Figure 7.1: Representative images from the OCT classification dataset. (Far left)
choroidal neovascularization (CNV) with neovascular membrane (white arrow-
heads) and associated subretinal fluid (arrows). (Middle left) Diabetic macular
edema (DME) with retinal-thickening-associated intraretinal fluid (arrows). (Mid-
dle right) Multiple drusen (arrowheads) present in early ARMD. (Far right) Nor-
mal retina with preserved foveal contour and absence of any retinal fluid/edema.
Reproduced from [50].
far as data augmentation, image normalization, SGD learning rate and momentum,
learning rate scheduler, and cross entropy loss. No image preprocessing was done
other than resizing images to the expected input size required for each respective
model. The networks were all run for 25 epochs. To investigate the effect of adding
layers, DenseNet-161, ResNet-34, and VGG-19 were run with the same settings, in
fixed-feature extractor and fine-tuning modes, for 25 epochs. The networks were
run on the same previously described computing environment on a GPU.
Network loss and accuracy over the epochs were tabulated and plotted. Each
model was evaluated with the test data using weights established at the last epoch.
As in part II, accuracy and quadratic weighted kappa were reported.
89
Chapter 8
Results
Tables 8.1 and 8.2 summarize the training and validation loss and accuracy
for each network, run in fixed-feature extractor and fine-tuning modes. Loss and
accuracy plots for 5 networks (AlexNet, DenseNet-121, Inception v3, ResNet-18,
and VGG-11) are plotted in figures 8.1 and 8.2, respectively. Several observations
are made:
(1) The training and valiation losses were much lower in fine-tuning vs. fixed
feature mode. In particular, the validation loss across the networks was on order
10 times less for fine-tuning compared to fixed-feature (mean loss 0.0682 vs. 0.4453)
(2) Within the fixed-feature extractor and fine-tuning modes, the loss was gen-
erally similar across the networks (table 8.1, standard deviation results).
(3) The training and validation accuracies were signficantly higher for fine-tuning
mode vs. fixed-feature extractor. In particular the validation accuracy across
90
the networks was much higher for fine-tuning (0.9778) vs. fixed-feature extractor
(0.8509).
(4) Within the fixed-feature extractor and fine-tuning modes, the accuracy was
generally similar across the networks (table 8.2, standard deviation results). In
particular, for fine-tuning mode, all the networks had >97% validation accuracy.
(5) Adding layers to the DenseNet, ResNet, and VGG networks (via DenseNet-161,
ResNet-34, and VGG-19, respectively) lowered the loss slightly in all cases. This
also increased the accuracies in all cases by very small amounts.
Table 8.1: OCT-based Classification Network loss results. Shown are the
loss values for each network at the last epoch. Values are grouped by whether the
network was used in fine-tuning or fixed feature extractor mode. All networks were
trained for 25 epochs.
Fixed-Feature Fine-Tuning
Network Training Validation Training Validation
AlexNet 0.6513 0.4168 0.2084 0.0921
DenseNet-121 0.6666 0.4937 0.1514 0.0665
DenseNet-161 0.6308 0.3513 0.1382 0.0599
Inception 0.7957 0.5926 0.1387 0.0595
ResNet-18 0.7212 0.4403 0.1666 0.0698
ResNet-34 0.7034 0.4386 0.1532 0.0665
VGG-11 0.6348 0.4156 0.1572 0.0679
VGG-19 0.6283 0.4134 0.1504 0.0630
Mean 0.6790 0.4453 0.1508 0.0682
Stddev 0.0545 0.0668 0.0093 0.0097
Figure 8.3 shows the network training to validation ratios. Except for a single
outlier for AlexNet early in training, all ratios were >1. In general, the ratio for
fine-tuning was greater than feature-extractor as the number of epochs progressed.
This implies that the networks were not over-fitting and the fitting profiles for
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Table 8.2: OCT-based Classification Network accuracy results. Shown are
the accuracy values for each network at the last epoch. Values are grouped by
whether the network was used in fine-tuning or fixed feature extractor mode. All
networks were trained for 25 epochs.
Fixed-Feature Fine-Tuning
Network Training Validation Training Validation
AlexNet 0.7716 0.8554 0.9271 0.9716
DenseNet-121 0.7529 0.8624 0.9471 0.9788
DenseNet-161 0.7671 0.8875 0.9518 0.9804
Inception 0.6995 0.8003 0.9516 0.9797
ResNet-18 0.7318 0.8464 0.9416 0.9765
ResNet-34 0.7393 0.8519 0.9459 0.9779
VGG-11 0.7706 0.8491 0.9447 0.9776
VGG-19 0.7752 0.8545 0.9475 0.9795
Mean 0.7510 0.8509 0.9447 0.9778
Stddev 0.245 0.0226 0.0074 0.0026
fine-tuning mode were better.
Lastly, the test dataset accuracy and quadratic weighted kappa results are
shown in tables 8.3 and 8.4, respectively. The accuracy for fine-tuning mode was
much higher than fixed-feature extractor (mean accuracy 95.1% for fine-tuning vs.
68.4% for fixed-feature extractor). Similarly, the quadratic weighted kappa was
much higher for fine-tuning compared to fixed-feature extractor (mean quadratic
weighted kappa 0.969 vs. 0.534).
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Table 8.3: OCT Classification Network Test Accuracy. Accuracy(%) is
indicated for the specified networks (all pre-trained) for fixed feature extractor
and fine tuning modes.
Network Fixed Feature Extractor Fine-Tuning
AlexNet 73.4 92.2
DenseNet-121 76.8 96.2
DenseNet-161 79.1 96.4
Inception-v3 25.0 92.4
ResNet-18 73.8 95.3
ResNet-34 74.5 95.8
VGG-11 69.6 95.5
VGG-19 75.1 96.9
Mean 68.4 95.1
Stdev 16.6 1.7
Table 8.4: OCT Classification Network Test Quadratic Weighted Kappa.
Quadratic weighted kappa is indicated for the specified networks (all pre-trained)
for fixed feature extractor and fine tuning modes. A generally agreed upon scale
is: <0.20(Poor), 0.21-0.40(Fair), 0.41-0.60(Moderate), 0.61-0.80(Good), and 0.81-
1.00(Very good).
Network Fixed Feature Extractor Fine-Tuning
AlexNet 0.517 0.944
DenseNet-121 0.647 0.983
DenseNet-161 0.676 0.976
Inception-v3 0.000 0.951
ResNet-18 0.607 0.968
ResNet-34 0.591 0.976
VGG-11 0.582 0.969
VGG-19 0.655 0.984
Mean 0.534 0.969
Stdev 0.207 0.014
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(a) AlexNet, fine-tuning.
(b) AlexNet, feature-extractor.
Figure 8.1: Plotted are the network training and validation loss over the epochs.
All networks were run pre-trained for 25 epochs.
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(c) DenseNet121, fine-tuning.
(d) DenseNet121, feature-extractor.
Figure 8.1: Plotted are the network training and validation loss over the epochs.
All networks were run pre-trained for 25 epochs.
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(e) Inception v3, fine-tuning.
(f) Inception v3, feature-extractor.
Figure 8.1: Plotted are the network training and validation loss over the epochs.
All networks were run pre-trained for 25 epochs.
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(g) ResNet-18, fine-tuning.
(h) ResNet-18, feature-extractor.
Figure 8.1: Plotted are the network training and validation loss over the epochs.
All networks were run pre-trained for 25 epochs.
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(i) VGG-11, fine-tuning.
(j) VGG-11, feature-extractor.
Figure 8.1: Plotted are the network training and validation loss over the epochs.
All networks were run pre-trained for 25 epochs.
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(a) AlexNet, fine-tuning.
(b) AlexNet, feature-extractor.
Figure 8.2: Plotted are the network training and validation accuracy over the
epochs. All networks were run pre-trained for 25 epochs.
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(c) DenseNet121, fine-tuning.
(d) DenseNet121, feature-extractor.
Figure 8.2: Plotted are the network training and validation accuracy over the
epochs. All networks were run pre-trained for 25 epochs.
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(e) Inception v3, fine-tuning.
(f) Inception v3, feature-extractor.
Figure 8.2: Plotted are the network training and validation accuracy over the
epochs. All networks were run pre-trained for 25 epochs.
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(g) ResNet-18, fine-tuning.
(h) ResNet-18, feature-extractor.
Figure 8.2: Plotted are the network training and validation accuracy over the
epochs. All networks were run pre-trained for 25 epochs.
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(i) VGG-11, fine-tuning.
(j) VGG-11, feature-extractor.
Figure 8.2: Plotted are the network training and validation accuracy over the
epochs. All networks were run pre-trained for 25 epochs.
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(a) AlexNet. (b) DenseNet121.
(c) Inception v3. (d) ResNet-18.
(e) VGG-11.
Figure 8.3: Plotted are the network training to validation ratios. All networks
were run pre-trained for 25 epochs.
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Chapter 9
Discussion
This part of the report analyzed the performance of transfer learning for an
inter-disease classification scheme of normal (no retinal disease), DME, CNV, and
drusen. In contrast, part II analyzed transfer learning for an intra-disease classifi-
cation scheme, specifically cases of no diabetic retinopathy vs. increasing severity
of diabetic retinopathy.
While a previous report [50] analyzed a single network (Inception v3), to the
best of my knowledge, no prior work has analyzed a suite of networks. Several key
findings were observed in this report:
(1) The validation accuracies at the end of training were significantly higher when
the networks were configured in fine-tuning compared to fixed-feature extractor
mode. On average, across the networks evaluated (table 8.2), the validation accu-
racy for fine-tuning was 0.9778 compared to 0.8509 for fixed-feature extractor.
(2) All the networks did very well, with validation accuracies >97% for fine-tuning
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mode. Adding layers to networks (specifically DenseNet, ResNet, and VGG) did
not significantly improve performance.
(3) The mean accuracy for all the networks using the test dataset was much higher
(95.1%) in fine-tuning mode compared to fixed-feature extractor (68.4%). A sim-
ilar finding occured with the quadratic weighted kappa, where fine-tuning had
a kappa of 0.969 (very good) while fixed-feature extractor had a kappa of 0.534
(moderate). The accuracy and quadratic weighted kappa for fixed-feature extrac-
tor were brought down by low values for Inception v3, however, similar findings
were observed when this network was excluded.
Interestingly, the best test accuracy (fine-tuning, 96.9%) of this inter-disease
classification scheme was much higher than the accuracy found in the intra-disease
classification scheme (fine-tuning, 77.5%) for diabetic retinopathy detection in part
II. This is expected, since the features that distinguish the classes in the inter-
disease scheme (normal, DME, CNV, and drusen) are much different and richer
than the more subtle features that distinguish cases of no diabetic retinopathy
compared to mild diabetic retinopathy, or mild diabetic retinopathy compared to
moderate diabetic retinopathy.
To investigate sources of error, confusion matrices were constructed (appendix
D). Certain patterns were observed:
(1) In fine-tuning mode, the networks generally did very well classifying normal,
DME, and CNV test cases. The sources of error mostly came from misclassifcation
of drusen test cases. The majority of these errors occured when the the network
106
misclassified the test case as CNV and ground truth was drusen. Presumably,
there were morphologic characteristics that confused the networks into classifying
these cases as CNV and further research is beneficial.
(2) In general, the majority of ground truth test cases of DME and CNV that
were misclassified by the networks in fixed-feature extractor mode were correctly
classified in fine-tuning mode. Although the misclassification of drusen substan-
tially improved from fixed-feature extractor to fine-tuning, there was still a small
portion of drusen test cases that were misclassified. For example, consider VGG-
11: in fixed-feature extractor mode 182 (72.8%) of 250 drusen test cases were
misclassified, which improved to 33 (13.2%) misclassifications with fine-tuning.
(3) Adding layers did not significantly improve the misclassification rates, except
for VGG-11 to -19 with fixed-feature extractor, where there was a significant de-
crease in misclassifications of DME and drusen.
Inception v3 was examined in more detail (figure D.1g and D.1h) because it
showed behaviour in fixed-feature extractor that deviated from the other networks.
The findings showed that: (1) for fixed-feature extractor, the network classifica-
tion broke down, whereby all the test cases were classified as CNV (Class 2). It
is unclear why this occured only for this particular network; (2) for fine-tuning,
this network correctly identified all normal and CNV cases, but misclassified 8% of
DME cases as CNV, 2% of drusen cases as normal, and 20.4% of drusen cases as
CNV. The network was re-run in fixed-feature mode and showed consistent results
of 24.5% test accuracy and 0.00 quadratic weighted kappa on the second run.
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Kermany et al. [50] described “results based adapting Inception v3 pretrained
on the ImageNet dataset. Retraining consisted of initializing the convolutional
layers with loaded pretrained weights and retraining the final, softmax layer to
recognize our classes from scratch. In this study, the convolutional layers were
frozen and used as fixed feature extractors.” Moreover, they report that “attempts
at fine-tuning the convolutional layers by unfreezing and updating the pretrained
weights on our medical images using backpropagation tended to decrease model
performance due to overfitting.” However, the results described in this report sup-
port the opposite conclusion, in that fine-tuning Inception v3 yielded much higher
accuracies, while the training to validation ratio plots did not imply overfitting.
It should be noted that Kermany et al. used Tensorflow while this study used
PyTorch. SGD with the same learning rate were used in both studies.
It should be noted as well that Kamble et al. [47] used Inception-Resnet-v2
fine-tuned in their study and reported 100% classification accuracy. They note
that their developed model was also compared to other fine tuned models, such as
Resnet-50 and Inception-v3. It is unclear why the implications of fine-tuning and
fixed-feature extractor differed between this thesis and Kermany et al. Further
study is warranted.
Lastly, several study limitations should be noted:
(1) The dataset provider allocated a relatively small number of test cases (1,000 in
total, with 250 cases from each class). Further evaluation with larger test datasets,
especially with varying degrees of image quality, would be insightful.
(2) The images were derived from one type of instrument (Spectralis OCT, Hei-
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delberg Engineering, Germany). Further study with other OCT vendor cameras
would be beneficial.
(3) The objective of the second part of this study was to evaluate transfer learning
for classification of DME, CNV, and drusen by OCT, rather than classification
of DME and ARMD by OCT. The rationale for this was two-fold: (a) CNV and
drusen, although associated with ARMD, can be seen in other retinal conditions
besides ARMD and it unclear from the methodology of Kermany et al. [50] if all
cases were from ARMD; and (b) the AREDS classification of ARMD recognizes
other morphologic features besides drusen and CNV, such as geographic atrophy,
which may signify ARMD and were not evaluated in the dataset used by this
report.
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Appendix A
List of abbreviations
AMT Amazon mechanical Turk
ARIA Automated retinal image analysis
ARMD Age-Related Macular Degeneration
BN Batch normalization
CNV choroidal neovascularization
DL Deep Learning
DME diabetic macular edema
DNN Deep neural network
DR diabetic retinopathy
JPEG Joint Photographic Experts Group
NPDR Non-proliferative diabetic retinopathy
OCT Optical coherence tomography
PDR Proliferative diabetic retinopathy
ResNet Residual Neural Network
VGG Visual Geometry Group
VTDR Vision-threatening diabetic retinopathy
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Appendix B
Review of Statistical Topics Used
in this Thesis
B.1 Sensitivity and Specificity
In assessing the performance of a diagnostic test, there are 4 cases to consider
in comparing the label predicted by a system (e.g. a deep learning network) versus
the true label assigned by a grader to that test label:
1. True positive (TP) - the predicted and true labels agree and the test case
has the disease.
2. True negative (TP) - the predicted and true labels agree and the test case
does not have the disease.
3. False Negative (FN) - the predicted label is that the test case does not
have the disease, while the true label is that the test case has the disease.
4. False positive (FP) - the predicted label is that the test case has the
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disease, while the true label is that the test case does not have the disease.
Sensitivity (also called the true positive rate, the recall, or probability of
detection [51] in some fields) measures the proportion of actual positives that are
correctly identified as such (e.g. the percentage of sick people who are correctly
identified as having the condition) and is defined by:
Sensitivity =
TP
TP + FN
(B.1)
Specificity (also called the true negative rate) measures the proportion of
actual negatives that are correctly identified as such (e.g. the percentage of healthy
people who are correctly identified as not having the condition) and is defined by:
Specificity =
TN
TN + FP
(B.2)
Accuracy is the percentage of cases where the predicted and true labels agree.
In a binary classification scheme, accuracy can by defined by:
Accuracy =
TP + TN
TP + TN + FP + FN
(B.3)
B.2 Wilcoxon signed-rank and Mann-Whitney U
Test
The Wilcoxon signed-rank test is a non-parametric statistical hypothesis test
used to compare two related samples, matched samples, or repeated measurements
on a single sample to assess whether their population mean ranks differ (i.e. it is
a paired difference test). It can be used as an alternative to the paired Student’s
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t-test, t-test for matched pairs, or the t-test for dependent samples when the
population cannot be assumed to be normally distributed. A Wilcoxon signed-rank
test is a nonparametric test that can be used to determine whether two dependent
samples were selected from populations having the same distribution[52]. See [52]
for details of the test procedure.
The Mann-Whitney U test is a nonparametric test of the null hypothesis
that it is equally likely that a randomly selected value from one sample will be less
than or greater than a randomly selected value from a second sample[53]. See [53]
for details of the test calculation.
B.3 Quadratic weighted kappa
Cohen’s kappa coefficient (κ) is a statistic which measures inter-rater agree-
ment for qualitative (categorical) items[54]. Kappa takes into account the possibil-
ity of agreement occuring by chance (i.e. guessing) and is a more robust measure
than simple percent agreement. For details of the kappa calculation, the reader
is referred to [55]. Kappa does not take into account the degree of disagreement
between observers and all disagreement is treated equally as total disagreement.
Therefore, a weighting scheme has been devised, with either linear or quadratic
weightings.1 A generally agreed upon scale for level of agreement is shown in table
B.1.
1For example see the medcalc implementation at https://www.medcalc.org/manual/kap
pa.php, which advised: Use linear weights when the difference between the first and second
category has the same importance as a difference between the second and third category, etc. If
the difference between the first and second category is less important than a difference between
the second and third category, etc., use quadratic weights.
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Table B.1: Kappa catagories.
κ Level of Agreement
<0.20 Poor
0.21-0.40 Fair
0.41-0.60 Moderate
0.61-0.80 Good
0.81-1.00 Very good
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Appendix C
Network loss and accuracy plots
This appendix is for reference purposes and is organized as so:
• Figure C.1 shows boxplots of the loss parameter for the 16 networks that were
evaluated. Each plot indicates whether pretrained or not-pretrained networks
were used, the phase of training (training or validation), and whether the
network was used in fine-tuning or fixed feature extractor mode.
• Figure C.2 shows boxplots of the accuracy parameter for the 16 networks that
were evaluated. Each plot indicates whether pretrained or not-pretrained
networks were used, the phase of training (training or validation), and whether
the network was used in fine-tuning or fixed feature extractor mode.
• Figures C.3-C.18 are the detailed plots of loss and accuracy data for each of
the 16 networks evaluated (table 1.1). All networks were run for 10 epochs.
• Figure C.19 shows boxplots comparing loss results for two groups (aggregate
of the 16 networks), where the groups are defined by a combination of 3
variables: (1) network pretrained or not pretrained; (2) training or validation
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phase; and (3) used in fine-tuning or fixed feature extractor mode.
• Figure C.20 shows boxplots comparing accuracy results for two groups (ag-
gregate of the 16 networks), where the groups are defined by a combination
of 3 variables: (1) network pretrained or not pretrained; (2) training or vali-
dation phase; and (3) used in fine-tuning or fixed feature extractor mode.
117
(a) Training Loss (Not pretrained, Fine-tuning)
(b) Training Loss (Not pretrained, Fixed Feature Extractor)
Figure C.1: Diabetic Retinopathy: Network loss boxplots.
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(c) Training Loss (Pretrained, Fine-tuning)
(d) Training Loss (Pretrained, Fixed Feature Extractor)
Figure C.1: Continued - Diabetic Retinopathy: Network loss boxplots.
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(e) Validation Loss (Not pretrained, Fine-tuning)
(f) Validation Loss (Not pretrained, Fixed Feature Extractor)
Figure C.1: Continued - Diabetic Retinopathy: Network loss boxplots.
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(g) Validation Loss (Pretrained, Fine-tuning)
(h) Validation Loss (Pretrained, Fixed Feature Extractor)
Figure C.1: Continued - Diabetic Retinopathy: Network loss boxplots.
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(a) Training Accuracy (Not pretrained, Fine-tuning)
(b) Training Accuracy (Not pretrained, Fixed Feature Extractor)
Figure C.2: Diabetic Retinopathy: Network accuracy boxplots.
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(c) Training Accuracy (Pretrained, Fine-tuning)
(d) Training Accuracy (Pretrained, Fixed Feature Extractor)
Figure C.2: Continued - Diabetic Retinopathy: Network accuracy boxplots.
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(e) Validation Accuracy (Not pretrained, Fine-tuning)
(f) Validation Accuracy (Not pretrained, Fixed Feature Extractor)
Figure C.2: Continued - Diabetic Retinopathy: Network accuracy boxplots.
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(g) Validation Accuracy (Pretrained, Fine-tuning)
(h) Validation Accuracy (Pretrained, Fixed Feature Extractor)
Figure C.2: Continued - Diabetic Retinopathy: Network accuracy boxplots.
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(a) Loss; Pretrained; Fine-tuning (b) Pretrained; Feature extractor
(c) Loss; Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy; Pretrained; Fine-tuning
(f) Accuracy; Pretrained; Feature extrac-
tor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.3: Diabetic Retinopathy: AlexNet loss and accuracy plots.
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(a) Loss; Pretrained; Fine-tuning (b) Loss; Pretrained; Feature extractor
(c) Loss, Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy; Pretrained; Fine-tuning
(f) Accuracy; Pretrained; Feature extrac-
tor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.4: Diabetic Retinopathy: DenseNet-121 loss and accuracy plots.
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(a) Loss; Pretrained; Fine-tuning (b) Loss; Pretrained; Feature extractor
(c) Loss; Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy; Pretrained; Fine-tuning (f) Accuracy Pretrained; Feature extractor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.5: Diabetic Retinopathy: DenseNet-161 loss and accuracy plots.
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(a) Loss; Pretrained; Fine-tuning (b) Loss; Pretrained; Feature extractor
(c) Loss; Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy; Pretrained; Fine-tuning
(f) Accuracy; Pretrained; Feature extrac-
tor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.6: Diabetic Retinopathy: DenseNet-169 loss and accuracy plots.
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(a) Loss; Pretrained; Fine-tuning (b) Loss; Pretrained; Feature extractor
(c) Loss; Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy Pretrained; Fine-tuning
(f) Accuracy; Pretrained; Feature extrac-
tor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.7: Diabetic Retinopathy: DenseNet-201 loss and accuracy plots.
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(a) Loss; Pretrained; Fine-tuning (b) Loss; Pretrained; Feature extractor
(c) Loss; Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy; Pretrained; Fine-tuning (f) Accuacy; Pretrained; Feature extractor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.8: Diabetic Retinopathy: Inception-v3 loss and accuracy plots.
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(a) Loss; Pretrained; Fine-tuning (b) Loss; Pretrained; Feature extractor
(c) Loss; Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy; Pretrained; Fine-tuning
(f) Accuracy; Pretrained; Feature extrac-
tor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.9: Diabetic Retinopathy: ResNet-18 loss and accuracy plots.
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(a) Loss; Pretrained; Fine-tuning (b) Loss; Pretrained; Feature extractor
(c) Loss; Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy; Pretrained; Fine-tuning
(f) Accuracy; Pretrained; Feature extrac-
tor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.10: Diabetic Retinopathy: ResNet-34 loss and accuracy plots.
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(a) Loss; Pretrained; Fine-tuning (b) Loss; Pretrained; Feature extractor
(c) Loss; Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy; Pretrained; Fine-tuning
(f) Accuracy; Pretrained; Feature extrac-
tor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.11: Diabetic Retinopathy: ResNet-50 loss and accuracy plots.
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(a) Loss; Pretrained; Fine-tuning (b) Loss; Pretrained; Feature extractor
(c) Loss; Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy; Pretrained; Fine-tuning
(f) Accuracy; Pretrained; Feature extrac-
tor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.12: Diabetic Retinopathy: ResNet-101 loss and accuracy plots.
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(a) Loss; Pretrained; Fine-tuning (b) Loss; Pretrained; Feature extractor
(c) Loss; Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy; Pretrained; Fine-tuning
(f) Accuracy; Pretrained; Feature extrac-
tor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.13: Diabetic Retinopathy: ResNet-152 loss and accuracy plots.
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(a) Loss; Pretrained; Fine-tuning (b) Loss; Pretrained; Feature extractor
(c) Loss; Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy; Pretrained; Fine-tuning
(f) Accuracy; Pretrained; Feature extrac-
tor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.14: Diabetic Retinopathy: VGG-11 loss and accuracy plots.
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(a) Loss; Pretrained; Fine-tuning (b) Loss; Pretrained; Feature extractor
(c) Loss; Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy; Pretrained; Fine-tuning
(f) Accuracy; Pretrained; Feature extrac-
tor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.15: Diabetic Retinopathy: VGG-11bn loss and accuracy plots.
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(a) Loss; Pretrained; Fine-tuning (b) Loss; Pretrained; Feature extractor
(c) Loss; Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy; Pretrained; Fine-tuning
(f) Accuracy; Pretrained; Feature extrac-
tor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.16: Diabetic Retinopathy: VGG-13 loss and accuracy plots.
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(a) Loss; Pretrained; Fine-tuning (b) Loss; Pretrained; Feature extractor
(c) Loss; Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy; Pretrained; Fine-tuning
(f) Accuracy; Pretrained; Feature extrac-
tor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.17: Diabetic Retinopathy: VGG-16 loss and accuracy plots.
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(a) Loss; Pretrained; Fine-tuning (b) Loss; Pretrained; Feature extractor
(c) Loss; Not Pretrained; Fine-tuning
(d) Loss; Not Pretrained; Feature extrac-
tor
(e) Accuracy; Pretrained; Fine-tuning
(f) Accuracy; Pretrained; Feature extrac-
tor
(g) Accuracy; Not Pretrained; Fine-tuning
(h) Accuracy; Not Pretrained; Feature ex-
tractor
Figure C.18: Diabetic Retinopathy: VGG-19 loss and accuracy plots.
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(a) p=0.002 (b) p=0.301
(c) p=0.002 (d) p=0.034
(e) p<0.001 (f) p=0.569
(g) p<0.001 (h) p=0.006
Figure C.19: Network loss boxplot comparisons. Each boxplot indicates the
two groups compared. Each label indicates 3 variables: if networks were pretrained
(P) or not pretrained (P), training (train) or validation phase, and evaluated as
a fixed feature extractor or as fine-tuning the networks. p-values indicated are
Wilcoxon signed-rank (C.19a-C.19h) or Mann-Whitney (C.19i-C.19l) tests com-
paring the two groups, with p < 0.05 indicating a statistically significant difference.
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(i) p=0.053 (j) p=0.462
(k) p=0.220 (l) p=0.084
Figure C.19: Network loss boxplot comparisons - continued. Each boxplot
indicates the two groups compared. Each label indicates 3 variables: if networks
were pretrained (P) or not pretrained (P), training (train) or validation phase,
and evaluated as a fixed feature extractor or as fine-tuning the networks. p-values
indicated are Wilcoxon signed-rank (C.19a-C.19h) or Mann-Whitney (C.19i-C.19l)
tests comparing the two groups, with p < 0.05 indicating a statistically significant
difference.
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(a) p=0.004 (b) p=0.642
(c) p=0.003 (d) p=0.006
(e) p=0.005 (f) p=0.248
(g) p=0.001 (h) p=0.001
Figure C.20: Network accuracy boxplot comparisons. Each boxplot indi-
cates the two groups compared. Each label indicates 3 variables: if networks were
pretrained (P) or not pretrained (P), training (train) or validation phase, and
evaluated as a fixed feature extractor or as fine-tuning the networks. p-values in-
dicated are Wilcoxon signed-rank (C.20a-C.20h) or Mann-Whitney (C.20i-C.20l)
tests comparing the two groups, with p < 0.05 indicating a statistically significant
difference. 144
(i) p=0.003 (j) p<0.001
(k) p=0.146 (l) p<0.001
Figure C.20: Network accuracy boxplot comparisons - continued. Each
boxplot indicates the two groups compared. Each label indicates 3 variables: if
networks were pretrained (P) or not pretrained (P), training (train) or validation
phase, and evaluated as a fixed feature extractor or as fine-tuning the networks. p-
values indicated are Wilcoxon signed-rank (C.20a-C.20h) or Mann-Whitney (C.20i-
C.20l) tests comparing the two groups, with p < 0.05 indicating a statistically
significant difference.
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Appendix D
OCT-based Classification
Confusion Matrices
This appendix shows the OCT-based classification confusion matrices for the
networks listed below, where each network was pre-trained and run in fixed-feature
extractor and fine-tuning modes. All networks were run for 25 epochs.
• AlexNet
• DenseNet-121
• DenseNet-161
• Inception v3
• ResNet-18
• ResNet-34
• VGG-11
• VGG-19
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(a) AlexNet: Fixed-feature extractor.
(b) AlexNet: Fine-tuning.
Figure D.1: OCT-based Classification Confusion Matrices.
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(c) DenseNet-121: Fixed-feature extractor.
(d) DenseNet-121: Fine-tuning.
Figure D.1: OCT-based classification Confusion Matrices.
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(e) DenseNet-161: Fixed-feature extractor.
(f) DenseNet-161: Fine-tuning.
Figure D.1: OCT-based classification Confusion Matrices.
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(g) Inception v3: Fixed-feature extractor.
(h) Inception v3: Fine-tuning.
Figure D.1: OCT-based classification Confusion Matrices.
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(i) ResNet-18: Fixed-feature extractor.
(j) ResNet-18: Fine-tuning.
Figure D.1: OCT-based classification Confusion Matrices.
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(k) ResNet-34: Fixed-feature extractor.
(l) ResNet-34: Fine-tuning.
Figure D.1: OCT-based classification Confusion Matrices.
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(m) VGG-11: Fixed-feature extractor.
(n) VGG-11: Fine-tuning.
Figure D.1: OCT-based classification Confusion Matrices.
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(o) VGG-19: Fixed-feature extractor.
(p) VGG-19: Fine-tuning.
Figure D.1: OCT-based classification Confusion Matrices.
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